JP2004250445A - Glycation inhibitor and its use - Google Patents
Glycation inhibitor and its use Download PDFInfo
- Publication number
- JP2004250445A JP2004250445A JP2004021332A JP2004021332A JP2004250445A JP 2004250445 A JP2004250445 A JP 2004250445A JP 2004021332 A JP2004021332 A JP 2004021332A JP 2004021332 A JP2004021332 A JP 2004021332A JP 2004250445 A JP2004250445 A JP 2004250445A
- Authority
- JP
- Japan
- Prior art keywords
- glycation
- extract
- glycation inhibitor
- lemon
- thyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036252 glycation Effects 0.000 title claims abstract description 57
- 239000003112 inhibitor Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 235000000556 Paullinia cupana Nutrition 0.000 claims abstract description 10
- 240000003444 Paullinia cupana Species 0.000 claims abstract description 10
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 10
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 9
- 241000508269 Psidium Species 0.000 claims abstract description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 8
- 244000061508 Eriobotrya japonica Species 0.000 claims abstract description 7
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims abstract description 7
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 7
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 6
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 6
- 235000017715 Thymus pulegioides Nutrition 0.000 claims abstract description 6
- 240000006001 Thymus serpyllum Species 0.000 claims abstract description 6
- 235000004054 Thymus serpyllum Nutrition 0.000 claims abstract description 6
- 244000004281 Eucalyptus maculata Species 0.000 claims abstract description 5
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 5
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 5
- 241000246358 Thymus Species 0.000 claims abstract description 5
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 5
- 235000002020 sage Nutrition 0.000 claims abstract description 5
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 5
- 231100000827 tissue damage Toxicity 0.000 claims abstract description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 4
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 4
- 241000218645 Cedrus Species 0.000 claims abstract description 4
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 4
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 4
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 4
- 230000000451 tissue damage Effects 0.000 claims abstract description 4
- 235000005881 Calendula officinalis Nutrition 0.000 claims abstract description 3
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 3
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 3
- 240000004784 Cymbopogon citratus Species 0.000 claims abstract description 3
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 3
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 3
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 3
- 244000068988 Glycine max Species 0.000 claims abstract description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 3
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 3
- 240000005561 Musa balbisiana Species 0.000 claims abstract description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 3
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 3
- 240000007926 Ocimum gratissimum Species 0.000 claims abstract description 3
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 3
- 240000000785 Tagetes erecta Species 0.000 claims abstract description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 3
- 241000219995 Wisteria Species 0.000 claims abstract description 3
- 235000021014 blueberries Nutrition 0.000 claims abstract description 3
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 3
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 3
- 235000013976 turmeric Nutrition 0.000 claims abstract description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract 3
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract 3
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract 2
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract 2
- 240000007817 Olea europaea Species 0.000 claims abstract 2
- 241000208680 Hamamelis mollis Species 0.000 claims description 25
- 229940118846 witch hazel Drugs 0.000 claims description 25
- 239000000419 plant extract Substances 0.000 claims description 19
- 208000026062 Tissue disease Diseases 0.000 claims description 12
- 240000007651 Rubus glaucus Species 0.000 claims description 11
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 11
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 241000220317 Rosa Species 0.000 claims description 10
- 244000307697 Agrimonia eupatoria Species 0.000 claims description 9
- 235000000125 common agrimony Nutrition 0.000 claims description 9
- 235000016970 Fragaria moschata Nutrition 0.000 claims description 7
- 244000307700 Fragaria vesca Species 0.000 claims description 7
- 235000014828 Fragaria vesca ssp. americana Nutrition 0.000 claims description 7
- 235000012660 Fragaria virginiana Nutrition 0.000 claims description 7
- 239000000177 juniperus communis l. berry Substances 0.000 claims description 7
- 240000000982 Malva neglecta Species 0.000 claims description 6
- 235000000060 Malva neglecta Nutrition 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 241000911175 Citharexylum caudatum Species 0.000 claims description 5
- 240000005183 Lantana involucrata Species 0.000 claims description 5
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 5
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 5
- 244000062730 Melissa officinalis Species 0.000 claims description 5
- 235000005135 Micromeria juliana Nutrition 0.000 claims description 5
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 5
- 240000002114 Satureja hortensis Species 0.000 claims description 5
- 235000007315 Satureja hortensis Nutrition 0.000 claims description 5
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 4
- 240000003553 Leptospermum scoparium Species 0.000 claims description 4
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 4
- 241000051611 Salacia oblonga Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 240000006914 Aspalathus linearis Species 0.000 claims description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 3
- 240000003538 Chamaemelum nobile Species 0.000 claims description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 235000009120 camo Nutrition 0.000 claims description 3
- 235000005607 chanvre indien Nutrition 0.000 claims description 3
- 235000014134 echinacea Nutrition 0.000 claims description 3
- 239000011487 hemp Substances 0.000 claims description 3
- 240000006054 Agastache cana Species 0.000 claims description 2
- 235000013668 Aloysia triphylla Nutrition 0.000 claims description 2
- 240000008554 Aloysia triphylla Species 0.000 claims description 2
- 244000208874 Althaea officinalis Species 0.000 claims description 2
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 2
- 240000000662 Anethum graveolens Species 0.000 claims description 2
- 235000005290 Annona glabra Nutrition 0.000 claims description 2
- 244000028477 Annona glabra Species 0.000 claims description 2
- 235000007258 Anthriscus cerefolium Nutrition 0.000 claims description 2
- 240000002022 Anthriscus cerefolium Species 0.000 claims description 2
- 239000009405 Ashwagandha Substances 0.000 claims description 2
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 claims description 2
- 244000003240 Caesalpinia gilliesii Species 0.000 claims description 2
- 241000723353 Chrysanthemum Species 0.000 claims description 2
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 claims description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 2
- 244000228088 Cola acuminata Species 0.000 claims description 2
- 235000010205 Cola acuminata Nutrition 0.000 claims description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 claims description 2
- 244000018436 Coriandrum sativum Species 0.000 claims description 2
- 244000133098 Echinacea angustifolia Species 0.000 claims description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 2
- 244000166124 Eucalyptus globulus Species 0.000 claims description 2
- 241000208688 Eucommia Species 0.000 claims description 2
- 241000208251 Gymnema Species 0.000 claims description 2
- 235000008418 Hedeoma Nutrition 0.000 claims description 2
- 235000005206 Hibiscus Nutrition 0.000 claims description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 2
- 235000010650 Hyssopus officinalis Nutrition 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 235000006770 Malva sylvestris Nutrition 0.000 claims description 2
- 235000014749 Mentha crispa Nutrition 0.000 claims description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 2
- 235000010679 Nepeta cataria Nutrition 0.000 claims description 2
- 240000009215 Nepeta cataria Species 0.000 claims description 2
- 235000011203 Origanum Nutrition 0.000 claims description 2
- 240000000783 Origanum majorana Species 0.000 claims description 2
- 241001261543 Orthriophis moellendorffi Species 0.000 claims description 2
- 240000004371 Panax ginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 241000198694 Passiflora pallida Species 0.000 claims description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 2
- 241001127637 Plantago Species 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 241001635574 Sabatia angularis Species 0.000 claims description 2
- 241000543810 Sasa veitchii Species 0.000 claims description 2
- 241000320380 Silybum Species 0.000 claims description 2
- 235000010841 Silybum marianum Nutrition 0.000 claims description 2
- 235000005865 Symphytum officinale Nutrition 0.000 claims description 2
- 240000002299 Symphytum officinale Species 0.000 claims description 2
- 240000004460 Tanacetum coccineum Species 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- 244000125380 Terminalia tomentosa Species 0.000 claims description 2
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 2
- 244000274883 Urtica dioica Species 0.000 claims description 2
- 235000009108 Urtica dioica Nutrition 0.000 claims description 2
- 235000001978 Withania somnifera Nutrition 0.000 claims description 2
- 240000004482 Withania somnifera Species 0.000 claims description 2
- 235000011472 cat’s claw Nutrition 0.000 claims description 2
- ZDKZHVNKFOXMND-UHFFFAOYSA-N epinepetalactone Chemical compound O=C1OC=C(C)C2C1C(C)CC2 ZDKZHVNKFOXMND-UHFFFAOYSA-N 0.000 claims description 2
- 235000008384 feverfew Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 235000001035 marshmallow Nutrition 0.000 claims description 2
- 235000021395 porridge Nutrition 0.000 claims description 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims description 2
- 239000009538 yokuinin Substances 0.000 claims description 2
- 244000302512 Momordica charantia Species 0.000 claims 2
- 230000001700 effect on tissue Effects 0.000 claims 2
- 235000003826 Artemisia Nutrition 0.000 claims 1
- 244000286893 Aspalathus contaminatus Species 0.000 claims 1
- 240000005250 Chrysanthemum indicum Species 0.000 claims 1
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims 1
- 244000163122 Curcuma domestica Species 0.000 claims 1
- 244000055850 Diospyros virginiana Species 0.000 claims 1
- 244000025221 Humulus lupulus Species 0.000 claims 1
- 244000024873 Mentha crispa Species 0.000 claims 1
- 235000009421 Myristica fragrans Nutrition 0.000 claims 1
- 244000270834 Myristica fragrans Species 0.000 claims 1
- 241000237502 Ostreidae Species 0.000 claims 1
- 240000004760 Pimpinella anisum Species 0.000 claims 1
- 240000005809 Prunus persica Species 0.000 claims 1
- 239000010233 Taheebo Substances 0.000 claims 1
- 240000007591 Tilia tomentosa Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 235000009052 artemisia Nutrition 0.000 claims 1
- 239000001702 nutmeg Substances 0.000 claims 1
- 235000020636 oyster Nutrition 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 40
- 241000196324 Embryophyta Species 0.000 abstract description 31
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 244000236655 Diospyros kaki Species 0.000 abstract description 3
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 2
- 244000008991 Curcuma longa Species 0.000 abstract description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 abstract description 2
- 241000218228 Humulus Species 0.000 abstract description 2
- 244000165082 Lavanda vera Species 0.000 abstract description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 abstract description 2
- 235000004347 Perilla Nutrition 0.000 abstract description 2
- 239000001102 lavandula vera Substances 0.000 abstract description 2
- 235000018219 lavender Nutrition 0.000 abstract description 2
- 235000013616 tea Nutrition 0.000 abstract description 2
- 244000148659 Acanthopanax sieboldianus Species 0.000 abstract 1
- 235000015559 Acanthopanax sieboldianus Nutrition 0.000 abstract 1
- 241000694401 Acer maximowiczianum Species 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 239000000899 Gutta-Percha Substances 0.000 abstract 1
- 244000267823 Hydrangea macrophylla Species 0.000 abstract 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 abstract 1
- 240000001740 Momordica dioica Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 241000498779 Myristica Species 0.000 abstract 1
- 240000000342 Palaquium gutta Species 0.000 abstract 1
- 235000003143 Panax notoginseng Nutrition 0.000 abstract 1
- 241000180649 Panax notoginseng Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 229920000588 gutta-percha Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000000469 ethanolic extract Substances 0.000 description 18
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- -1 ethanol Chemical class 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000008057 potassium phosphate buffer Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 241000222518 Agaricus Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000003788 bath preparation Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000722949 Apocynum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 241000510032 Ellipsaria lineolata Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 241000131739 Oncorhynchus masou rhodurus Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019220 whole milk chocolate Nutrition 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Abstract
Description
本発明は植物の抽出物又はその成分を有効成分とし、グリケーションにより生じる各種組織障害の予防及び治療・改善効果を有する、安全性の高いグリケーション阻害剤及びその利用に関する。 The present invention relates to a highly safe glycation inhibitor having a plant extract or a component thereof as an active ingredient, having an effect of preventing, treating and improving various tissue disorders caused by glycation, and a use thereof.
近年、環境条件の悪化や生活様式の変化、社会生活の複雑化に伴うストレスの増加等により、老化が促進される要因が増えている。しかし一方で、日本人の平均寿命が延び、高齢者の占める割合が増えるとともに、若々しく健康に暮らすことの大切さが見直されてきている。従って、老化の進行を抑制することは、万人の待ち望んでいるところでもある。 In recent years, factors that promote aging are increasing due to deterioration in environmental conditions, changes in lifestyles, and an increase in stress accompanying the complication of social life. On the other hand, however, the average life expectancy of Japanese people has increased and the proportion of elderly people has increased, and the importance of living young and healthy has been reconsidered. Therefore, suppressing the progress of aging is something everyone is waiting for.
老化の進行には様々な要因が関与しているが、その要因の１つに非酵素的蛋白糖化反応が挙げられている。これは、還元糖とアミノ酸又は蛋白質の結合により、蛋白質本来の機能に障害をもたらす反応であり、グリケーション（褐変反応）と呼ばれている。生体内の種々の生理機能は蛋白質が司っており、糖化された蛋白は本来の機能を発揮できず、各種の機能障害をもたらすと考えられる。このグリケーションの初期段階反応物質は、アマドリ化合物と呼ばれる蛋白質と糖の結合物であり、更にこの反応は、脱水、重合を経て蛍光性、褐色化、分子内及び分子間架橋形成を特徴とする終末糖化物質(advanced glycation end products: ＡＧＥ)になる。 Various factors are involved in the progress of aging, and one of the factors is a non-enzymatic protein saccharification reaction. This is a reaction in which the intrinsic function of the protein is impaired due to the binding of the reducing sugar and the amino acid or protein, and is called glycation (browning reaction). Various physiological functions in the living body are controlled by proteins, and glycated proteins cannot exert their original functions and are thought to cause various functional disorders. The early stage reactant of this glycation is a protein-sugar conjugate called an Amadori compound, and this reaction is characterized by dehydration, polymerization, fluorescence, browning, intra- and intermolecular cross-link formation. It becomes advanced glycation end products (AGE).
これらＡＧＥは、加齢とともに生体内に蓄積し、加齢で認められる種々の組織障害、例えば、皮膚、血管壁、関節、肺等の結合組織の硬化（例えば、非特許文献１〜４参照）に関連することが示唆されており、皮膚の肥厚やしわの形成、動脈硬化、関節炎、心肺機能低下等の原因になると考えられている。また、白内障（例えば、非特許文献５参照）にも関連していると考えられている。また、グリケーションは加齢による組織障害の原因となるだけではなく、日光性弾力繊維症、アルツハイマー病、糖尿病合併症等の疾病に関与することが推測されている。例えば、日光性弾力線維症の皮膚組織にはＡＧＥの一種であるカルボキシメチルリジン（ＣＭＬ）が検出されており、ＣＭＬの蓄積が深いしわや皮膚組織の硬化等の病変に関わっていることが示唆されている（例えば、非特許文献６参照）。また、アルツハイマー病におけるβ-アミロイドペプチドの脳内蓄積にＡＧＥが関与していることが示唆されている（例えば、非特許文献７参照）。
These AGEs accumulate in the living body with aging, and various tissue disorders observed at aging, for example, hardening of connective tissues such as skin, blood vessel walls, joints, and lungs (for example, see Non-Patent
更に、糖尿病における腎障害、網膜症にＡＧＥの蓄積が関係していることも示唆されている(例えば、非特許文献８参照)。このようなＡＧＥの蓄積に対し、その元となるグリケーションを阻害する薬剤としてアミノグアニジンが知られている。この化合物は、糖尿病合併症である網膜症、腎障害、神経障害に有効であることがモデル動物で確認されており（例えば、非特許文献９参照）、糖尿病合併症の治療薬として米国で治験が進められている。しかし、アミノグアニジン服用により頭痛、悪心等の副作用が報告されており、医師の指導のもとに服用する必要がある。 Furthermore, it has been suggested that AGE accumulation is related to renal disorder and retinopathy in diabetes (for example, see Non-Patent Document 8). Aminoguanidine is known as a drug that inhibits glycation as a source of such AGE accumulation. This compound has been confirmed to be effective in diabetic complications such as retinopathy, renal disorder and neuropathy in model animals (for example, see Non-Patent Document 9), and is studied in the United States as a therapeutic agent for diabetic complications. Is being promoted. However, side effects such as headache and nausea have been reported by taking aminoguanidine, and it is necessary to take it under the guidance of a doctor.
従って、本発明の課題は、高いグリケーション阻害効果を有し、かつ副作用を生じさせることのない、安全性の高いグリケーション阻害剤を提供することにある。 Therefore, an object of the present invention is to provide a highly safe glycation inhibitor which has a high glycation inhibitory effect and does not cause side effects.
本発明者等は、このような事情に鑑み、上記課題を解決すべく鋭意研究を行った結果、特定の植物の抽出物が高いグリケーション阻害効果を有することを見出し、本発明を完成した。 In view of such circumstances, the present inventors have conducted intensive studies to solve the above problems, and as a result, have found that an extract of a specific plant has a high glycation inhibitory effect, and completed the present invention.
すなわち本発明は、アグリモニー、アシュワガンダ、アニス、アマチャヅル、甘葉懸鈎子、銀杏、ウイキョウ、ウイッチヘーゼル、ウコン、エキナセア、エゾウコギ、エルダー、エルバ・マテ、オオバコ、オリーブ、オレガノ、オレンジ、柿、カキドオシ、カミツレ、ガラナ、含羞草、菊、ギムネマ、キャッツクロー、キャットニップ、キラウェイ、キンギンカ、グァバ、クコヨウ、くまざさ、クミクスチン、黒大豆、くわ、シナモン、ケツメイシ、ゴーヤ、コーラナッツ、ゴカヒ、ゴツコラ、コリアンダー、コンフリー、サキシマスオウ、サフラワー、サラシア・オブロンガ、サンザシ、サンシチニンジン、しそ、ジュウヤク、ジュニパーベリー、ジンジャー、杉、スギナ、ステビア、スペアミント、セイジ、セイボリー、セイヨウサンザシ、仙▲査▼、タイム、タヒボ、ダンデライオン、チャービル、チャノキ、チャボトケイソウ、チョウジ、デイジー、ディル、トチュウ、ニクズク、南姜、ネトル、ハイビスカス、白猪母邱、白花蛇舌草、ハゴロモソウ、バジル、ハス、半枝連、ヒース、ピーチ、ヒソップ、びわ、フィーバーフュー、フクギ、藤、プランタゴ・サイリュウム、ブルーベリー、ブルーマロウ、ペニーロイヤル、ベニバナ、ペパーミント、ホップ、ポリジ、ポンドアップル、マシュマロー、マジョラム、マリーゴールド、マレイン、マロウスモール、マロウブルー、ミフクラギ、ミルクシスル、メグスリノキ、メデゥスイート、モッカ、ヤエヤマ アオキ、ヤクルマギク、ヤローフラワー、ユーカリ、ヨクイニン、ヨモギ、ラズベリー、ラベンダー、リンデン、ルイボス、レモングラス、レモンタイム、レモンバーベナ、レモンバーム、ローズヒップ、ローズピンクバッツ、ローズマリー、ローズレッド、ローレル、羅布麻、ワイルドストロベリーより選ばれる植物の抽出物の１種又は２種以上を含有することを特徴とするグリケーション阻害剤を提供するものである。 That is, the present invention relates to agrimony, ashwagandha, anise, amachaworu, kanha hook, ginkgo, fennel, witch hazel, turmeric, echinacea, eleuthero, elder, elba mate, plantain, olives, oregano, orange, persimmon, persimmon, chamomile. , Guarana, shrimps, chrysanthemum, gymnema, cat's claw, catnip, killaway, kinginka, guava, kucoyo, kumazasa, cumixtin, black soybean, hoe, cinnamon, ketsumeishi, bitter gourd, cola nut, kokahi, gotsukola, coriander, comfrey , Sashimisuo, safflower, sarasia oblonga, hawthorn, sanshin ginseng, shiso, jujuya, juniper berry, ginger, cedar, horsetail, stevia, spearmint, sage, savory, sorghum , Sen ▲ ▼, thyme, tahibo, dandelion, chervil, chanoki, chabotokeisou, chouji, daisy, dill, eucommia, nutmegium, nan-gyo, nettle, hibiscus, white-mau-mo-gu, white flower snake tongue grass, hagoromosou, basil, Lotus, half-branch, heath, peach, hyssop, loquat, feverfew, fukugi, wisteria, plantago syllium, blueberry, bluemallow, pennyroyal, safflower, peppermint, hop, porridge, pondapple, marshmallow, marjoram, marigold , Malein, mallow small, mallow blue, mif kuragi, milk thistle, megusurinoki, medi suite, mokka, yaeyama aoki, yakumagiku, yarrow flower, eucalyptus, yokuinin, mugwort, raspberry, lavender, linden, le Contains one or more plant extracts selected from ibos, lemongrass, lemon thyme, lemon verbena, lemon balm, rose hips, rose pink butts, rosemary, rose red, laurel, lufu hemp, wild strawberry A glycation inhibitor is provided.
また、本発明は上記グリケーション阻害剤を含有する組織障害予防・治療剤並びに組織障害予防・治療効果を有する飲食品及び外用剤を提供するものである。 The present invention also provides a prophylactic / therapeutic agent for tissue disorders containing the above-mentioned glycation inhibitor, and a food / beverage product and an external preparation having a prophylactic / therapeutic effect on tissue disorders.
本発明のグリケーション阻害剤は、高いグリケーション阻害効果を有するものである。 The glycation inhibitor of the present invention has a high glycation inhibitory effect.
従って、本発明のグリケーション阻害剤はグリケーション或いはグリケーションによって生じる終末糖化物質（ＡＧＥ）等の蓄積によって引き起こされる、各種組織障害の予防及び治療・改善効果を得ることができるものである。 Therefore, the glycation inhibitor of the present invention is capable of preventing, treating and improving various tissue disorders caused by glycation or accumulation of advanced glycation endogenous substances (AGE) caused by glycation.
本発明のグリケーション阻害剤（以下、単に「阻害剤」という）の有効成分は、下記の表１及び表２に示す植物の抽出物である。 The active ingredient of the glycation inhibitor (hereinafter, simply referred to as “inhibitor”) of the present invention is a plant extract shown in Tables 1 and 2 below.
これら植物の抽出物の中でも、アグリモニー、銀杏、ウイッチヘーゼル、オレガノ、セイボリー、グァバ、クミクスチン、サラシア・オブロンガ、しそ、チャノキ、ジュニパーベリー、杉、セイジ、タイム、チョウジ、甘葉懸鈎子、ハゴロモソウ、ヒース、びわ、エルバ・マテ、メグスリノキ、ユーカリ、ヨモギ、ラズベリー、羅布麻、ルイボス、レモンタイム、レモンバーム、ローズヒップ、ローズマリー、ローズレッド、ワイルドストロベリー、ガラナ、フクギより選ばれる植物の抽出物が好ましく、特に、アグリモニー、ウィッチヘーゼル、甘葉懸鈎子、ハゴロモソウ、メグスリノキ、チャノキ、サラシア・オブロンガ、ガラナより選ばれる植物の抽出物が好ましい。 Among the extracts of these plants, Agrimony, Ginkgo, Witch Hazel, Oregano, Savory, Guava, Cumixtine, Salacia oblonga, Shiso, Chanoki, Juniper berry, Cedar, Sage, Thyme, Thyme, Clover, Kangomoso, Heath , Loquat, Elba Mate, Megusulinoki, Eucalyptus, mugwort, raspberry, Rafu-ma, rooibos, lemon thyme, lemon balm, rose hips, rosemary, rose red, wild strawberry, guarana, plant extract selected from Fukugi, In particular, an extract of a plant selected from Agrimony, Witch Hazel, Amago Suspension, Hagoromoso, Meguslinoki, Chanoki, Salacia oblonga, and Guarana is preferred.
これら抽出物は、１種又は２種以上で本発明の阻害剤の有効成分として使用することができる。 One or more of these extracts can be used as an active ingredient of the inhibitor of the present invention.
上記植物の抽出物の製造方法は特に制限されるものではなく、通常用いられる方法により製造することができる。また、抽出条件も特に制約はなく、例えば、上記植物の各種部位（全草、花、萼、種子、果実、葉、枝、樹皮、根皮、根茎、根等）をそのまま又は裁断、粉砕あるいは細紛した後、搾取又は溶媒で抽出することにより製造される。 The method for producing the plant extract is not particularly limited, and the plant extract can be produced by a commonly used method. The extraction conditions are not particularly limited. For example, various parts of the plant (whole plant, flower, calyx, seed, fruit, leaf, branch, bark, root bark, rhizome, root, etc.) can be used as they are or cut, crushed or It is manufactured by finely pulverizing, extracting or extracting with a solvent.
このうち、溶媒を用いた抽出は、一般に使用する溶媒に合わせて常圧〜加圧下で常温〜溶媒の沸点の温度条件下で１０分〜１週間程度行えばよい。抽出に使用する溶媒としては、植物種や処理工程にあわせて通常用いられる溶媒を適宜選択して用いればよく、例えば、水やアルコール類（例えば、メタノール、無水エタノール、エタノール等の低級アルコール、又はプロピレングリコール、１,３−ブチレングリコール等の多価アルコール）、アセトン等のケトン類、ジエチルエーテル、ジオキサン、アセトニトリル、酢酸エチルエステル等のエステル類又はキシレン、ベンゼン、クロロホルム等の有機溶媒が挙げられる。なお、食品や化粧品素材として用いる場合等、有機溶媒が残留が好ましくない場合は、特に水やエタノール等を選択することが好ましい。これらの溶媒は単独で用いることもできるが、２種類以上を任意に組み合わせて使用することもできる。 Among these, extraction using a solvent may be performed for about 10 minutes to 1 week under a temperature condition of normal pressure to normal pressure and normal temperature to the boiling point of the solvent in accordance with a generally used solvent. As the solvent used for the extraction, a solvent usually used in accordance with the plant species and the treatment step may be appropriately selected and used, for example, water and alcohols (eg, methanol, anhydrous ethanol, lower alcohols such as ethanol, or Polyhydric alcohols such as propylene glycol and 1,3-butylene glycol); ketones such as acetone; esters such as diethyl ether, dioxane, acetonitrile and ethyl acetate; and organic solvents such as xylene, benzene and chloroform. In addition, when the organic solvent is not preferable, such as when using as a food or cosmetic material, it is particularly preferable to select water, ethanol, or the like. These solvents can be used alone or in combination of two or more.
具体的には、例えば以下の方法が使用できる。すなわち、植物原体あるいは乾燥物を細砕し、抽出溶媒を５〜２０倍量加え、常圧下、室温で１週間程度静置、又は抽出溶媒の沸点付近で１０〜３０分程抽出してから濾過して得られた濾液を減圧乾固あるいは凍結乾燥して植物抽出物を得る。 Specifically, for example, the following method can be used. That is, the plant body or the dried product is pulverized, the extraction solvent is added in an amount of 5 to 20 times, and the mixture is allowed to stand at room temperature under normal pressure for about one week, or extracted at about the boiling point of the extraction solvent for about 10 to 30 minutes. The filtrate obtained by filtration is dried under reduced pressure or freeze-dried to obtain a plant extract.
上記のようにして得られた植物の抽出物はそのままの状態で使用することもできるが、必要に応じ、その効力に影響のない範囲で更に脱臭、脱色等の精製処理を加えても良い。このような精製処理としては、通常の手段を任意に選択して行えば良く、例えば濾過又はイオン交換樹脂や活性炭カラム等を用い、吸着・脱色・精製等を行なえば良い。更に、凍結乾燥又は濃縮処理等により溶液状、ペースト状、ゲル状、又は粉末状の精製物を得ることができる。 The plant extract obtained as described above can be used as it is, but if necessary, a purification treatment such as deodorization and decolorization may be added as far as the effect is not affected. Such a purification treatment may be performed by arbitrarily selecting a usual means. For example, filtration, ion exchange resin, activated carbon column, or the like may be used to perform adsorption, decolorization, purification, or the like. Furthermore, a purified product in the form of a solution, paste, gel, or powder can be obtained by freeze-drying or concentration treatment.
本発明の阻害剤は、上記のようにして得られた植物抽出物をそのまま、あるいは公知の医薬品担体と組合せ、製剤化することにより調製される。この阻害剤は、組織障害予防・治療剤等の医薬品や、医薬部外品として使用できるが、化粧品等の外用剤あるいは飲食品に配合することにより、組織障害予防・治療効果を有する外用剤あるいは飲食品とすることもできる。 The inhibitor of the present invention is prepared by formulating the plant extract obtained as described above as it is or in combination with a known pharmaceutical carrier. This inhibitor can be used as a drug or a quasi-drug such as an agent for preventing or treating tissue disorders. It can also be a food or drink.
具体的に本発明の阻害剤を含有する組織障害予防・治療剤等の医薬品や医薬部外品を調製するには、本発明の阻害剤と通常の医薬品や医薬部外品に使用される分散補助剤、賦形剤等の担体や添加剤と混合し、粉剤、液剤、カプセル剤、懸濁剤、乳剤、シロップ剤、エリキシル剤、顆粒剤、丸剤、錠剤、トローチ剤、リモナーデ剤等の内服剤や、ゲル、乳液状、クリーム、軟膏、発布剤、入浴剤等の外用剤の形とすれば良い。 Specifically, to prepare a pharmaceutical or quasi-drug such as a tissue disorder prevention / treatment agent containing the inhibitor of the present invention, the inhibitor of the present invention and a dispersion used in ordinary pharmaceuticals or quasi-drugs are used. Mix with auxiliaries, excipients and other carriers and additives to form powders, solutions, capsules, suspensions, emulsions, syrups, elixirs, granules, pills, tablets, troches, limonades, etc. It may be in the form of an internal preparation or an external preparation such as a gel, an emulsion, a cream, an ointment, a patch or a bath.
上記担体としては、マンニトール、乳糖、デキストラン等の水溶性の単糖類、オリゴ糖類又は多糖類；ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース等のゲル形成性又は水溶性のセルロース類；結晶性セルロース、α―セルロース、架橋カルボキシメチルセルロースナトリウム及びそれらの誘導体等の水吸収性でかつ水難溶性のセルロース類；ヒドロキシプロピル澱粉、カルボキシメチル澱粉、架橋澱粉、アミロース、アミロペクチン、ペクチン及びそれらの誘導体等の水吸収性でかつ水難溶性の多糖類；アラビアガム、トラガントガム、グリコマンナン及びそれらの誘導体等の水吸収性でかつ水難溶性のガム類；ポリビニルピロリドン、架橋ポリアクリル酸及びその塩、架橋ポリビニルアルコール、ポリヒドロキシエチルメタクリレート及びそれらの誘導体等の架橋ビニル重合体類；リン脂質、コレステロール等のリポソーム等分子集合体を形成する脂質類糖を挙げることができる。 Examples of the carrier include water-soluble monosaccharides, oligosaccharides or polysaccharides such as mannitol, lactose and dextran; gel-forming or water-soluble celluloses such as hydroxypropylcellulose, hydroxypropylmethylcellulose and methylcellulose; crystalline cellulose, α -Water-absorbable and poorly water-soluble celluloses such as cellulose, crosslinked sodium carboxymethylcellulose and derivatives thereof; water-absorbable celluloses such as hydroxypropyl starch, carboxymethyl starch, crosslinked starch, amylose, amylopectin, pectin and derivatives thereof. And water-insoluble polysaccharides; water-absorbing and water-insoluble gums such as gum arabic, tragacanth, glycomannan and derivatives thereof; polyvinylpyrrolidone, cross-linked polyacrylic acid and salts thereof, and cross-linked polyvinyl alcohol , Polyhydroxyethyl methacrylate and crosslinked vinyl polymers such as derivatives thereof; may be mentioned phospholipids, the lipids sugar to form liposomes, such as molecular aggregate such as cholesterol.
また、添加剤としては微生物培養代謝物、紫外線吸収／遮断剤、美白剤、メラニン色素還元／分解剤、ターンオーバーの促進作用／細胞賦活剤、収斂剤、活性酸素消去剤、抗酸化剤、過酸化脂質生成抑制剤、抗炎症剤、殺菌・消毒薬、保湿剤、頭髪用剤、酸化剤、染料剤、栄養強化剤、乳製品、保湿剤、ホルモン類、ｐＨ調整剤、キレート剤、防腐・防バイ剤、清涼剤、安定化剤、乳化剤、動・植物性蛋白質又はその分解物、動・植物性多糖類又はその分解物、動・植物性糖蛋白質又はその分解物、血流促進剤、消炎剤・抗アレルギー剤、細胞賦活剤、角質溶解剤、創傷治療剤、増泡剤、増粘剤、口腔用剤、消臭・脱臭剤、苦味料、調味料、酵素等を挙げることができる。 Additives include microbial culture metabolites, ultraviolet light absorbing / blocking agents, whitening agents, melanin pigment reducing / decomposing agents, turnover promoting / cell activators, astringents, active oxygen scavengers, antioxidants, Lipid oxidation inhibitor, anti-inflammatory agent, disinfectant, disinfectant, moisturizer, hair agent, oxidizer, dye agent, nutritional enhancer, dairy product, moisturizer, hormones, pH adjuster, chelating agent, preservative Antibacterial agent, cooling agent, stabilizer, emulsifier, animal / vegetable protein or its degradation product, animal / vegetable polysaccharide or its degradation product, animal / vegetable glycoprotein or its degradation product, blood flow promoter, Anti-inflammatory agents / anti-allergic agents, cell activators, keratolytic agents, wound healing agents, foaming agents, thickeners, oral agents, deodorants / deodorants, bitters, seasonings, enzymes, etc. .
本発明の阻害剤は、グリケーション阻害作用を有するものであり、これを含有する組織障害予防・治療剤は、グリケーションにより生じる動脈硬化症、白内障、アルツハイマー症、腎不全、透析製アミロイドーシス、結合組織硬化に伴う各種疾患、日光弾力線維症、皮膚の肥厚等の各種組織障害の予防及び治療・改善効果を有するものである。 The inhibitor of the present invention has a glycation inhibitory action, and the preventive / therapeutic agent for tissue damage containing the inhibitor is glycation-induced arteriosclerosis, cataract, Alzheimer's disease, renal failure, amyloidosis produced by dialysis, binding It has an effect of preventing, treating and improving various tissue disorders such as various diseases associated with tissue hardening, solar elastic fibrosis, and thickening of the skin.
上記組織障害予防・治療剤の投与量としては、剤形や疾患等に合わせて適宜調整すればよいが、内服剤であれば、製剤全量中、前記植物抽出物を固形分換算で、０.５〜６０質量％（以下、単に「％」という）、好ましくは５〜６０％、特に好ましくは５〜１０％の範囲で配合すればよい。一方、外用剤であれば、製剤全量中、固形分換算で、０.０００１〜３０％、好ましくは０.００１〜２０％、特に好ましくは０.５〜２０％の範囲で配合すればよい。更に、入浴剤として使用する場合は、２００〜３００Ｌの浴湯対し外用剤と同程度の濃度になるように処方を考慮すれば良い。 The dosage of the above-mentioned agent for preventing or treating tissue disorders may be appropriately adjusted according to the dosage form, disease, etc., and in the case of an oral agent, the total amount of the plant extract in the total amount of the preparation is 0.1% in terms of solid content. The amount may be 5 to 60% by mass (hereinafter, simply referred to as "%"), preferably 5 to 60%, particularly preferably 5 to 10%. On the other hand, if it is an external preparation, it may be blended in the range of 0.0001 to 30%, preferably 0.001 to 20%, particularly preferably 0.5 to 20% in terms of solid content in the whole amount of the preparation. Further, when used as a bathing agent, the formulation may be considered so that the concentration of the bath water of 200 to 300 L is almost the same as that of the external preparation.
一方、本発明の阻害剤を含有する化粧品等の外用剤も、本発明の阻害剤を化粧料原料等に有効量添加する以外は通常の化粧品等の外用剤を製造するのと同様に製造される。使用される化粧料原料は上記の組織障害予防・治療剤において、担体および添加剤として例示した物のうち、化粧料等の外用剤に使用が認められるものを使用することができる。 On the other hand, external preparations such as cosmetics containing the inhibitor of the present invention are also produced in the same manner as those for producing external preparations for ordinary cosmetics, etc., except that an effective amount of the inhibitor of the present invention is added to cosmetic raw materials and the like. You. Cosmetic raw materials to be used include those exemplified as carriers and additives in the above-mentioned agents for preventing and treating tissue disorders, which are approved for use in external preparations such as cosmetics.
更に、本発明の阻害剤を含有する飲食品は、本発明の阻害剤を飲食品原料等に有効量添加すること以外は通常の飲食品を製造するのと同様に製造される。 Furthermore, foods and drinks containing the inhibitor of the present invention are produced in the same manner as ordinary foods and drinks except that an effective amount of the inhibitor of the present invention is added to raw materials for food and drink.
これら飲食品の例としては、パン、ビスケット、ホットケーキ、麺、錠菓等のデンプンを主体とする食品、チーズ、バター、ヨーグルト等の乳製品、ガム、キャンディー、和菓子等の菓子類、ハム、ソーセージ等の畜肉食品、ちくわ、かまぼこ等の魚肉食品、魚介類食品、ドレッシング、醤油、ジャム、ふりかけ等の調味料、茶、ジュース、清涼飲料、乳酸菌飲料、酒類等の飲料等が挙げられ、これら飲食品への本発明阻害剤の配合量は、前記植物抽出物の固形分換算で０.０１〜６０％、好ましくは０.０１〜２０％、特に好ましくは０.１〜１５％程度とすれば良い。 Examples of these foods and drinks include bread, biscuits, hot cakes, noodles, starch-based foods such as tablets, dairy products such as cheese, butter, yogurt, gums, candy, sweets such as Japanese sweets, ham, Meat foods such as sausages, fish foods such as chikuwa, kamaboko, seafoods, dressings, soy sauce, jam, seasonings such as sprinkles, teas, juices, soft drinks, lactic acid drinks, drinks such as liquor, and the like. The amount of the inhibitor of the present invention to be added to food or drink is about 0.01 to 60%, preferably about 0.01 to 20%, particularly preferably about 0.1 to 15% in terms of the solid content of the plant extract. Good.
次に実施例を挙げて本発明を詳細に説明するが、本発明はこれらに何ら限定されるものではない。 Next, the present invention will be described in detail with reference to examples, but the present invention is not limited thereto.
製 造 例 １
植物熱水抽出物の製造：
表３に記載の各植物の２５ｇを５００ｍＬの沸騰水中にて常圧下で３０分間抽出した。得られた抽出液をガーゼで濾過した後、室温まで冷却し、凍結乾燥して植物熱水抽出物（実施品１〜１１１）を得た。
Manufacturing example 1
Production of plant hot water extract:
25 g of each plant described in Table 3 was extracted in 500 mL of boiling water under normal pressure for 30 minutes. The obtained extract was filtered through gauze, cooled to room temperature, and freeze-dried to obtain a hot water extract of plants (Examples 1-111).
製 造 例 ２
植物エタノール抽出物の製造：
表４に記載の各植物の乾燥体の２.５ｇを５０ｍＬのエタノール中にて、常圧下、室温で１週間抽出した。得られた抽出液をガーゼで濾過した後、濾液を減圧乾固して植物エタノール抽出物（実施品１１２〜２１４）を得た。
Manufacturing example 2
Production of plant ethanol extract:
2.5 g of the dried product of each plant described in Table 4 was extracted in 50 mL of ethanol at room temperature under normal pressure for one week. After the obtained extract was filtered through gauze, the filtrate was dried under reduced pressure to obtain a plant ethanol extract (Examples 112 to 214).
製 造 例 ３
植物含水エタノール抽出物の製造：
ウイッチヘーゼル（幹）、ローズマリー、ジュニパーベリー、ヨモギ、びわ（葉）、グァバ（葉）の各植物の２５ｇを５００ｍＬの５０％含水エタノール中にて、常圧下、室温で１週間抽出した。得られた抽出液をガーゼで濾過した後、濾液を減圧乾固して植物含水エタノール抽出物を得た。
Manufacturing example 3
Preparation of plant hydrous ethanol extract:
25 g of each of the witch hazel (stem), rosemary, juniper berry, mugwort, loquat (leaf), and guava (leaf) plants were extracted in 500 mL of 50% aqueous ethanol at normal pressure and room temperature for one week. After the obtained extract was filtered with gauze, the filtrate was dried under reduced pressure to obtain a plant-containing ethanol extract.
試 験 例 １
植物熱水抽出物のグリケーション阻害作用の測定：
グリケーションの初期段階反応物質は、アマドリ化合物と呼ばれる蛋白質と糖の結合物である。更にこの初期段階反応物質は脱水、重合を経て蛍光を持つ終末糖化物質（ＡＧＥ）を形成する。従って、ＡＧＥ量を測定することで、グリケーションの阻害作用が測定できる。
Test example 1
Measurement of glycation inhibitory activity of plant hot water extract:
The early stage reactant of glycation is a protein-sugar conjugate called an Amadori compound. In addition, this early stage reactant undergoes dehydration and polymerization to form a fluorescent advanced saccharified substance (AGE). Therefore, the glycation inhibitory action can be measured by measuring the amount of AGE.
検体としては、製造例１で得られた植物熱水抽出物（実施品１〜１１１）を用い、ＡＧＥ量の測定はナカザワらの方法（Nakazawa-H et al., J. Agric. Food Chem., 48, 180-185 (2000)）を一部改変して行った。なお、既知のグリケーション阻害剤であるアミノグアニジンを本試験の陽性対照として用いた。 As the specimen, the plant hot water extract obtained in Production Example 1 (Examples 1-111) was used, and the amount of AGE was measured by the method of Nakazawa-H et al. (Nakazawa-H et al., J. Agric. Food Chem. , 48, 180-185 (2000)). In addition, aminoguanidine which is a known glycation inhibitor was used as a positive control in this test.
各検体は蒸留水で最終濃度１０、２、０.４、０.０８、０.０１６、０.００３２ｍｇ／ｍＬになるように調整し、スクリューキャップ付き試験管に５００μＬずつ分注後オートクレーブ滅菌して試料とした。また、陽性対照は、アミノグアニジンを蒸留水で２００、１００、５０、２５、１２.５、６.２５ｍＭになるように調製し、これを滅菌済みの試験管にフィルター滅菌しながら５００μＬずつ分注して調製した。なお、対照には蒸留水を用いた。 Each sample was adjusted to a final concentration of 10, 2, 0.4, 0.08, 0.016, 0.0032 mg / mL with distilled water, dispensed 500 μL each into a test tube with a screw cap, and sterilized in an autoclave. To make a sample. As a positive control, aminoguanidine was prepared with distilled water to have a concentration of 200, 100, 50, 25, 12.5, and 6.25 mM, and this was dispensed into sterilized test tubes by filter-sterilizing 500 μL. Prepared. Note that distilled water was used as a control.
上記の検体、陽性対照および対照の各々の試験管にフィルター滅菌済みの４０ｍｇ／ｍＬの牛血清アルブミン（bovine serum albumin, fractionＶ; Sigma社製、以下、「ＢＳＡ」という）、１ＭのＤ−フラクトース（最終濃度０.５Ｍ）を含有する４００ｍＭリン酸カリウム緩衝液（ｐＨ７.４、最終濃度２００ｍＭ）を５００μＬずつ添加し、３７℃で７日間遮光下で反応させた。ブランクとしては、Ｄ−フラクトースが入っていない試験管を用意した。 The test sample, the positive control, and the control were each sterilized with filter-sterilized 40 mg / mL bovine serum albumin (fraction V; manufactured by Sigma, hereinafter referred to as “BSA”) and 1M D-fructose ( 500 mM of a 400 mM potassium phosphate buffer solution (pH 7.4, final concentration: 200 mM) containing a final concentration of 0.5 M) was added thereto, and reacted at 37 ° C. for 7 days under light shielding. A test tube containing no D-fructose was prepared as a blank.
反応終了後、各試験管に１０％トリクロロ酢酸溶液１ｍＬを添加、攪拌し、冷却遠心（４℃、３,０００ｒｐｍ、５分）を行った後、上清をデカントで除去し、更に沈殿を５％トリクロロ酢酸溶液２ｍＬで２回洗浄した。洗浄終了後、沈殿を２００ｍＭリン酸カリウム緩衝液（ｐＨ７.４）２ｍＬに溶解した。溶解した沈殿物２００μＬを蛍光測定用９６穴プレートに移し、蛍光プレートリーダーＳＰＥＣＴＲＡｍａｘ ＧＥＭＩＮＩ ＸＳ（モレキュラーデバイス社）を用いて、励起波長３５０ｎｍ、蛍光波長４２５ｎｍで蛍光を測定し、以下の数式１に従いグリケーション阻害率を算出した。 After the reaction was completed, 1 mL of a 10% trichloroacetic acid solution was added to each test tube, stirred, centrifuged at 4 ° C. (3,000 rpm, 5 minutes), the supernatant was decanted, and the precipitate was further removed. Washed twice with 2 mL of a% trichloroacetic acid solution. After the washing was completed, the precipitate was dissolved in 2 mL of a 200 mM potassium phosphate buffer (pH 7.4). 200 μL of the dissolved precipitate was transferred to a 96-well plate for fluorescence measurement, and the fluorescence was measured at an excitation wavelength of 350 nm and a fluorescence wavelength of 425 nm using a fluorescence plate reader SPECTRAmax GEMINI XS (Molecular Devices). The inhibition rate was calculated.
さらに、横軸に試料の濃度、縦軸にグリケーション阻害率をとった対数グラフを作成し、５０％阻害活性を示す濃度（ＩＣ５０）を算出した。得られた結果を表３に示す。 Further, a logarithmic graph was prepared in which the concentration of the sample was plotted on the horizontal axis and the glycation inhibition rate was plotted on the vertical axis, and the concentration (IC 50 ) showing 50% inhibitory activity was calculated. Table 3 shows the obtained results.
（ 結 果 ）
表３に示した通り、各植物抽出物は何れもＡＧＥの形成を阻害し、グリケーション阻害効果が認められた。また特に、ウイッチヘーゼル（幹）、ジュニパーベリー、ハゴロモソウ、ルイボス、ローズレッド、ウイッチヘーゼル（葉）、チャノキ（茎葉）、セイボリー、グァバ（葉）、ヒース、甘葉懸鈎子、ユーカリ、チョウジ、アグリモニー、オレガノ、ラズベリー（葉）、ワイルドストロベリー、レモンバーム、ローズマリー、タイム、ヨモギ、サラシア・オブロンガ、セイジ、銀杏（葉）、杉（葉）、レモンタイム（葉）、メグスリノキ、クミクスチン、びわ（葉）、エルバ・マテ、しそ、マンネンロウ、ローズヒップ、羅布麻のＩＣ５０は、アミノグアニジンのＩＣ５０、０.２８ｍｇ／ｍＬと同等、あるいはそれ以上の値を示し、優れたグリケーション阻害作用を有することが確認された。
(Result)
As shown in Table 3, each of the plant extracts inhibited the formation of AGE, and a glycation inhibitory effect was observed. In particular, witch hazel (stem), juniper berry, hagoromosou, rooibos, rose red, witch hazel (leaf), chanoki (foliage), savory, guava (leaf), heath, kanpaku hook, eucalyptus, butterfly, agrimony, Oregano, raspberry (leaf), wild strawberry, lemon balm, rosemary, thyme, mugwort, saracia oblonga, sage, ginkgo (leaf), cedar (leaf), lemon thyme (leaf), megslinoki, cumixtin, loquat (leaf), Elba mate, perilla, rosemary, rose hip, the IC 50 of Apocynum hemp, IC 50 of aminoguanidine, equivalent to 0.28 mg / mL, or shows a more values, to have excellent glycation inhibitory effect confirmed.
試 験 例 ２
植物エタノール抽出物のグリケーション阻害作用の測定（１）：
検体としては、製造例２で得られた植物エタノール抽出物（実施品１１２〜２１４）を用いた。測定は試験例１の方法を一部改変して行った。即ち、各検体をエタノールで０.４ｍｇ／ｍＬになるように調整し、滅菌済みの試験管にフィルター滅菌しながら５００μＬずつ分注し、試料とした。また、陽性対照としては、アミノグアニジンを蒸留水で０.４ｍｇ／ｍＬになるように調整し、これを滅菌済みの試験管にフィルター滅菌しながら５００μＬずつ分注したものを用いた。
Test example 2
Measurement of glycation inhibition effect of plant ethanol extract (1):
As the specimen, the plant ethanol extract obtained in Production Example 2 (Examples 112 to 214) was used. The measurement was performed by partially modifying the method of Test Example 1. That is, each sample was adjusted to 0.4 mg / mL with ethanol, and 500 μL each was dispensed into a sterilized test tube while filter-sterilizing the sample to obtain a sample. In addition, as a positive control, aminoguanidine adjusted to 0.4 mg / mL with distilled water, and 500 μL each of which was dispensed into a sterilized test tube with filter sterilization was used.
一方、ＢＳＡを４０ｍｇ／ｍＬ、Ｄ−ｆｒｕｃｔｏｓｅを１Ｍになるように０.４Ｍリン酸カリウム緩衝液（ｐＨ７.４）に溶解し、更に、この溶液５容に対し、蒸留水を４容加えた後、フィルターで滅菌処理し、ＢＳＡ−ｆｒｕｃｔｏｓｅ反応液とした。 On the other hand, BSA was dissolved at 40 mg / mL and D-fructose at 1 M in a 0.4 M potassium phosphate buffer (pH 7.4), and 4 volumes of distilled water were added to 5 volumes of this solution. Thereafter, the mixture was sterilized with a filter to obtain a BSA-fractose reaction solution.
試験は、上記ＢＳＡ−ｆｒｕｃｔｏｓｅ反応液を、オートクレーブ滅菌したねじ口試験管に無菌的に９００μＬずつ分注し、更に試料又は陽性対照を１００μＬずつ添加した。これらの試験管を遮光下で３７℃、７日間反応させた。なお、対照にはエタノールを１００μＬ添加したのみのものを用い、ブランクにはＤ−ｆｒｕｃｔｏｓｅが入っていないＢＳＡ溶液を用意した。 In the test, the BSA-fructose reaction solution was aseptically dispensed into an autoclave-sterilized screw-cap test tube in an amount of 900 μL, and a sample or a positive control was further added in an amount of 100 μL each. These test tubes were reacted at 37 ° C. for 7 days under light shielding. As a control, a sample to which only 100 μL of ethanol was added was used, and as a blank, a BSA solution containing no D-fractose was prepared.
反応終了後、各試験管に１０％トリクロロ酢酸溶液を１ｍＬ加えて攪拌し、冷却遠心（４℃、３,０００ｒｐｍ、５分）を行った後、上清をデカントで除去し、更に沈殿を５％トリクロロ酢酸溶液２ｍＬで２回洗浄した。洗浄終了後、沈殿を２００ｍＭリン酸カリウム緩衝液（ｐＨ７.４）２ｍＬに溶解した。この溶液２００μＬを蛍光測定用９６穴プレートに移し、蛍光プレートリーダーＳＰＥＣＴＲＡｍａｘ ＧＥＭＩＮＩ ＸＳ（モレキュラーデバイス社）を用いて、励起波長３５０ｎｍ、蛍光波長４２５ｎｍで蛍光を測定し、前述の式１に従いグリケーション阻害率（メイラード反応阻害率）を算出した。得られた結果を表４に示す。 After the completion of the reaction, 1 mL of a 10% trichloroacetic acid solution was added to each test tube, and the mixture was stirred and centrifuged at 4 ° C. (3,000 rpm, 5 minutes). Washed twice with 2 mL of a% trichloroacetic acid solution. After the washing was completed, the precipitate was dissolved in 2 mL of a 200 mM potassium phosphate buffer (pH 7.4). 200 μL of this solution was transferred to a 96-well plate for fluorescence measurement, and the fluorescence was measured at an excitation wavelength of 350 nm and a fluorescence wavelength of 425 nm using a fluorescence plate reader SPECTRAmax GEMINI XS (Molecular Devices). (Maillard reaction inhibition rate) was calculated. Table 4 shows the obtained results.
（ 結 果 ）
表４に示した通り、抽出溶媒にエタノールを用いた場合でも、各植物抽出物は何れもＡＧＥの形成を阻害し、グリケーション阻害効果が認められた。また特に、ウィッチヘーゼル（幹）、ウィッチヘーゼル（葉）、ハゴロモソウ、フクギ、ガラナ、甘葉懸鈎子、チャノキ（茎葉）、アグリモニー、サラシア・オブロンガ、メグスリノキは、アミノグアニジンと同等、あるいはそれ以上の値を示し、優れたグリケーション阻害作用を有することが確認された。
(Result)
As shown in Table 4, even when ethanol was used as the extraction solvent, each of the plant extracts inhibited AGE formation, and a glycation inhibitory effect was observed. In particular, witch hazel (stem), witch hazel (leaf), hagoromosou, fukugi, guarana, sweet-leaved hook, chamomile (foliage), agrimony, salasia oblonga, and megusulinoki have values equal to or higher than aminoguanidine. And it was confirmed to have an excellent glycation inhibitory action.
試 験 例 ３
植物エタノール抽出物のグリケーション阻害作用の測定（２）：
検体としては、製造例２で得られた実施品のうち、試験例２で効果の高かったウィッチヘーゼル（幹）、ウィッチヘーゼル（葉）、ハゴロモソウ、フクギ、ガラナ、甘葉懸鈎子、チャノキ（茎葉）、アグリモニー、サラシア・オブロンガを用いた。これら検体はエタノールで０.２〜０.００２ｍｇ／ｍＬになるように調整し、試験に供した。測定は試験例２の方法に従い、グリケーション阻害率及びＩＣ５０を算出した。得られた結果を表５に示す。
Test example 3
Measurement of glycation inhibitory effect of plant ethanol extract (2):
Among the samples obtained in Production Example 2 as samples, the witch hazel (stem), witch hazel (leaf), Hagoromosou, fukugi, guarana, kanobaku hook, tea tree (foliage) which were highly effective in Test Example 2 were obtained. ), Agrimony and Salacia oblonga. These samples were adjusted to 0.2 to 0.002 mg / mL with ethanol and used for the test. The measurement was performed according to the method of Test Example 2 to calculate the glycation inhibition rate and IC 50 . Table 5 shows the obtained results.
（ 結 果 ）
表５に示したように、何れの植物抽出物もＡＧＥの形成を阻害し、優れたグリケーション阻害効果を示した。特に、ウィッチヘーゼル（幹）、ウィッチヘーゼル（葉）、ハゴロモソウ、フクギ、ガラナ、甘葉懸鈎子、チャノキ（茎葉）、アグリモニーはアミノグアニジンと同等、あるいはそれ以上の値を示し、低濃度であっても優れたグリケーション阻害作用を有することが確認された。
(Result)
As shown in Table 5, all the plant extracts inhibited the formation of AGE and showed an excellent glycation inhibitory effect. In particular, witch hazel (stem), witch hazel (leaf), hagoromosou, fukugi, guarana, sweet-leaf hook, tea tree (foliage) and aggrimony show values equal to or higher than aminoguanidine, and low concentrations. Was also confirmed to have an excellent glycation inhibitory action.
製 造 例 ４
ウィッチヘーゼル（幹）熱水抽出物の調製：
ウィッチヘーゼル（刻み乾燥樹皮）５０ｇを量りとり、沸騰水１Ｌ中に入れて３０分間煮出した。室温に放置して冷ました後、３枚重ねのガーゼで漉し、抽出液を凍結乾燥して、抽出粉末６.８ｇ（収率１３.６％）を得た。
Manufacturing example 4
Preparation of witch hazel (stem) hot water extract:
50 g of witch hazel (chopped dry bark) was weighed, placed in 1 L of boiling water, and boiled for 30 minutes. After leaving it to cool at room temperature, it was strained with three layers of gauze, and the extract was freeze-dried to obtain 6.8 g of extract powder (13.6% yield).
製 造 例 ５
ウィッチヘーゼル（葉）熱水抽出物の調製：
ウィッチヘーゼル（刻み乾燥葉）５０ｇを量りとり、沸騰水１Ｌ中に入れて３０分間煮出した。室温に放置して冷ました後、３枚重ねのガーゼで漉して、抽出液を凍結乾燥して、抽出粉末７.２ｇ（収率１４.４％）を得た。
Manufacturing example 5
Preparation of witch hazel (leaf) hot water extract:
50 g of witch hazel (chopped dried leaves) was weighed, placed in 1 L of boiling water, and boiled for 30 minutes. After allowing to cool to room temperature, the extract was sieved with three layers of gauze, and the extract was freeze-dried to obtain 7.2 g (14.4% yield) of an extract powder.
製 造 例 ６
ハゴロモソウ熱水抽出物の調製：
ハゴロモソウ（刻み乾燥全草）５０ｇを量りとり、沸騰水１Ｌ中に入れて３０分間煮出した。室温に放置して冷ました後、３枚重ねのガーゼで漉し、抽出液を凍結乾燥して、抽出粉末１０.６ｇ（収率２１.２％）を得た。
Manufacturing example 6
Preparation of the extract of hot water sprouts:
50 g of Hagoromoso (chopped and dried whole plant) was weighed, placed in 1 L of boiling water, and boiled for 30 minutes. After leaving it to stand at room temperature to cool, it was strained with three layers of gauze, and the extract was freeze-dried to obtain 10.6 g (yield: 21.2%) of an extract powder.
製 造 例 ７
ウィッチヘーゼル（幹）エタノール抽出物の調製：
ウィッチヘーゼル（刻み乾燥樹皮）２.５ｇを量りとり、エタノール５０ｍＬ中に浸漬し、遮光下で室温１週間放置した。濾紙で漉した後、濾液を１００ｍＬ容のナスフラスコに入れてロータリーエバポレーターで減圧乾固し、エタノール抽出物２３０ｍｇ（収率９.２％）を得た。
Manufacturing example 7
Preparation of witch hazel (stem) ethanol extract:
2.5 g of witch hazel (chopped dry bark) was weighed, immersed in 50 mL of ethanol, and allowed to stand at room temperature for 1 week under light shielding. After straining with filter paper, the filtrate was put into a 100 mL eggplant-shaped flask and dried under reduced pressure with a rotary evaporator to obtain 230 mg (yield: 9.2%) of an ethanol extract.
製 造 例 ８
ウィッチヘーゼル（葉）エタノール抽出物の調製：
ウィッチヘーゼル（刻み乾燥葉）２.５ｇを量りとり、エタノール５０ｍＬ中に浸漬し、遮光下で室温１週間放置した。濾紙で漉した後、濾液を１００ｍＬ容のナスフラスコに入れてロータリーエバポレーターで減圧乾固し、エタノール抽出物３６０ｍｇ（収率１４.４％）を得た。
Manufacturing example 8
Preparation of witch hazel (leaf) ethanol extract:
2.5 g of witch hazel (chopped dried leaves) was weighed, immersed in 50 mL of ethanol, and allowed to stand at room temperature for 1 week under light shielding. After straining with filter paper, the filtrate was put into a 100 mL eggplant-shaped flask and dried under reduced pressure with a rotary evaporator to obtain 360 mg of ethanol extract (14.4% yield).
製 造 例 ９
ハゴロモソウエタノール抽出物の調製：
ハゴロモソウ（刻み乾燥全草）２.５ｇを量りとり、エタノール５０ｍＬ中に浸漬し、遮光下で室温１週間放置した。濾紙で漉した後、濾液を１００ｍＬ容のナスフラスコに入れてロータリーエバポレーターで減圧乾固し、エタノール抽出物１６０ｍｇ（収率６.４％）を得た。
Manufacturing example 9
Preparation of Echinacea purpurea ethanol extract:
2.5 g of Hagoromoso (chopped and dried whole plant) was weighed, immersed in 50 mL of ethanol, and allowed to stand at room temperature for 1 week under light shielding. After straining with a filter paper, the filtrate was put into a 100 mL eggplant-shaped flask and dried under reduced pressure with a rotary evaporator to obtain 160 mg (yield: 6.4%) of an ethanol extract.
製 造 例 １０
ラズベリー（果実）熱水抽出物の調製（１）：
ラズベリー（生果実）の６０ｇにイオン交換水２００ｍＬを加え、常圧下で３０分間煮沸して抽出液を得た。次いでこの抽出液を室温まで冷却した後、ろ紙で濾過し、凍結乾燥して熱水抽出物３.１４ｇ（収率５.２％）を得た。
Manufacturing example 10
Preparation of raspberry (fruit) hot water extract (1):
200 mL of ion-exchanged water was added to 60 g of raspberry (raw fruit), and the mixture was boiled under normal pressure for 30 minutes to obtain an extract. Next, the extract was cooled to room temperature, filtered through filter paper, and freeze-dried to obtain 3.14 g (yield 5.2%) of a hot water extract.
上記で得られた熱水抽出物について試験例１と同様にグリケーション阻害作用を測定した。その結果、ラズベリー（果実）熱水抽出物のＩＣ５０は０.１１２ｍｇ／ｍｌであった。 The glycation inhibitory effect of the hot water extract obtained above was measured in the same manner as in Test Example 1. As a result, the IC 50 of the raspberry (fruit) hot water extract was 0.112 mg / ml.
製 造 例 １１
ラズベリー（果実）熱水抽出物の調製（２）：
ラズベリー（冷凍果実）の５７.８ｇにイオン交換水２００ｍＬを加え、常圧下で３０分間煮沸して抽出液を得た。次いでこの抽出液を室温まで冷却した後、ろ紙で濾過し、凍結乾燥して熱水抽出物４.８ｇ（収率８.３％）を得た。
Manufacturing example 11
Preparation of raspberry (fruit) hot water extract (2):
200 mL of ion-exchanged water was added to 57.8 g of raspberry (frozen fruit), and the mixture was boiled under normal pressure for 30 minutes to obtain an extract. Next, the extract was cooled to room temperature, filtered with a filter paper, and freeze-dried to obtain 4.8 g (8.3% yield) of a hot water extract.
上記で得られた熱水抽出物について試験例１と同様にグリケーション阻害作用を測定した。その結果、ラズベリー（果実）熱水抽出物のＩＣ５０は０.１０８ｍｇ／ｍｌであった。 The glycation inhibitory effect of the hot water extract obtained above was measured in the same manner as in Test Example 1. As a result, the IC 50 of the raspberry (fruit) hot water extract was 0.108 mg / ml.
試 験 例 ４
動物体内における植物熱水抽出物のグリケーション阻害作用の測定：
検体としては、製造例１で得られたグアバ（葉）熱水抽出物（実施品９）およびワイルドストロベリー（葉）熱水抽出物（実施品１７）を用いた。また、動物としては、６週齢の雄性脳卒中易発症高血圧ラット（ＳＨＲ−ＳＰ／Ｉｚｍ）を１８匹用いた。ラットは１週間の予備飼育後、コントロール、グアバ（葉）熱水抽出物（ＧｖＥｘ）、ワイルドストロベリー（葉）熱水抽出物（ＷＳＥｘ）投与群の３群（各６匹）に分け、それぞれ、表６の組成の飼料を４週間与えて飼育した。これら各群のラットの１週間ごとの体重と１日あたりの摂餌量を測定した。その結果を図１および図２に示した。
Test example 4
Measurement of the glycation inhibitory effect of plant hot water extract in animals:
Guava (leaf) hot water extract (Example 9) and wild strawberry (leaf) hot water extract (Example 17) obtained in Production Example 1 were used as samples. As animals, 18 6-week-old male stroke-prone hypertensive rats (SHR-SP / Izm) were used. After pre-breeding for one week, the rats were divided into three groups (six in each) of a control, a guava (leaf) hot water extract (GvEx), and a wild strawberry (leaf) hot water extract (WSEx) administration group. The feed having the composition shown in Table 6 was fed for 4 weeks and bred. The weekly body weight and daily food consumption of the rats in each of these groups were measured. The results are shown in FIG. 1 and FIG.
４週間飼育後の各群のラットを麻酔した後、放血死させ、胸部大動脈を摘出した。摘出した大動脈を脱脂後、凍結乾燥を行い、細かく破砕した。次いで、これの一定量を取り、プロナーゼで２４時間処理した後、上清を回収し、サンプルとした。このサンプルの蛍光強度を励起波長３７０ｎｍ、発光波長４３０ｎｍで測定し、ＡＧＥ量を算出した。その結果を図３に示した。なお、蛍光強度とＡＧＥ量の関係は、例えば、文献（J. Hypartension, 17(4), 1999., p483, 左段８〜２４行目）に記載されている。 After breeding for 4 weeks, each group of rats was anesthetized, exsanguinated, and the thoracic aorta was isolated. The excised aorta was defatted, freeze-dried, and finely crushed. Next, an aliquot of this was taken and treated with pronase for 24 hours, after which the supernatant was recovered and used as a sample. The fluorescence intensity of this sample was measured at an excitation wavelength of 370 nm and an emission wavelength of 430 nm, and the AGE amount was calculated. The result is shown in FIG. The relationship between the fluorescence intensity and the AGE amount is described, for example, in the literature (J. Hypartension, 17 (4), 1999., p483, left column, lines 8 to 24).
（ 結 果 ）
各群のラットの１週間ごとの体重と１日あたりの摂餌量に有意な差は認められなかった。また、血管中のＡＧＥ量はコントロール群と比べＷＳＥｘ群およびＧｖＥｘ群の両方で減少していた。
(Result)
No significant difference was observed between the weekly body weight and the daily food consumption of the rats in each group. Further, the amount of AGE in the blood vessels was decreased in both the WSEx group and the GvEx group as compared with the control group.
以下に本発明によるグリケーション阻害剤の配合例を、典型的な実施例として挙げ説明する。 Examples of the glycation inhibitor according to the present invention will be described below as typical examples.
実 施 例 １
乳液：
製造例３により得られた、ウィッチヘーゼル（幹）、ローズマリー、ジュニパーベリー、ヨモギの各植物の植物含水エタノール抽出物を用いて乳液を作成した。
Example 1
Latex:
An emulsion was prepared using the plant-containing ethanol extract of each plant of witch hazel (stem), rosemary, juniper berry, and mugwort obtained in Production Example 3.
（ 成 分 ） （ 質 量 ％ ）
１．スクワラン ５.０
２．オリーブ油 ５.０
３．ホホバ油 ５.０
４．セチルアルコール １.５
５．グリセリンモノステアレート ２.０
６．ポリオキシエチレン（２０）セチルエーテル ３.０
７．ポリオキシエチレン（２０）ソオルビタンモノオレート ２.０
８．１，３−ブチレングリコール １.０
９．グリセリン ２.０
１０．植物含水エタノール抽出物 ５.０
１１．香料 適 量
１２．防腐剤 適 量
１３．精製水 残 部
(Ingredient) (Mass%)
1. Squalane 5.0
2. Olive oil 5.0
3. Jojoba oil 5.0
4. Cetyl alcohol 1.5
5. Glycerin monostearate 2.0
6. Polyoxyethylene (20) cetyl ether 3.0
7. Polyoxyethylene (20) soorbitan monooleate 2.0
8.1 1,3-butylene glycol 1.0
9. Glycerin 2.0
10. Plant water-containing ethanol extract 5.0
11. Fragrance
得られた乳液は、使用感にも優れた極めて有用なものであった。 The obtained emulsion was very useful with an excellent feeling upon use.
実 施 例 ２
顆粒浴用剤：
製造例２により得られた、ウィッチヘーゼル（幹）、ローズマリー、ヨモギの各植物の植物エタノール抽出物を用いて顆粒浴用剤を作成した。
Example 2
Granule bath preparation:
Granule bath preparations were prepared using plant ethanol extracts of witch hazel (stem), rosemary, and mugwort plants obtained in Production Example 2.
（ 成 分 ） （ 質 量 ％ ）
１．炭酸水素ナトリウム ６０.０
２．無水硫酸ナトリウム ３０.０
３．ホウ砂 ５.０
４．植物エタノール抽出物 ５.０
(Ingredient) (Mass%)
1. Sodium bicarbonate 60.0
2. Anhydrous sodium sulfate 30.0
3. Borax 5.0
4. Plant ethanol extract 5.0
得られた浴用剤は、使用感にも優れた極めて有用なものであった。 The resulting bath agent was very useful with an excellent feeling upon use.
実 施 例 ３
薬剤：
以下に示す薬剤を混和して、その混合物を打錠した。なお、植物抽出物としては試験例３でグリケーション阻害作用を確認した実施品を使用した。
Example 3
Drugs:
The following drugs were mixed and the mixture was tableted. In addition, the practical product which confirmed the glycation inhibition effect in Test Example 3 was used as the plant extract.
（ 成 分 ） （１錠当たりの質量（ｍｇ ））
１．植物抽出物 １０
２．乳糖 １９０
３．バレイショデンプン ３９
４．微結晶セルロース ３０
５．合成ケイ酸アルミニウム ３０
６．ステアリン酸カルシウム １
(Ingredient) (Mass per tablet (mg))
1. Plant extract 10
2. Lactose 190
3. Potato starch 39
4. Microcrystalline cellulose 30
5. Synthetic aluminum silicate 30
6.
得られた錠剤は、安定なものであり、服用し易いものであった。 The tablets obtained were stable and easy to take.
実 施 例 ４
清涼飲料水：
製造例６で得られたハゴロモソウの熱水抽出物１００ｍｇと砂糖５ｇを炭酸ソーダ水１００ｍＬに混合し、清涼飲料水を製造した。
Example 4
Soft drinks:
100 mg of the hot water extract of Agaricus officinalis obtained in Production Example 6 and 5 g of sugar were mixed with 100 mL of sodium carbonate water to produce a soft drink.
得られた清涼飲料は、淡黄色の飲料であり、清涼感のある味も良好なものであった。 The obtained soft drink was a light yellow drink and had a good refreshing taste.
実 施 例 ５
チョコレート：
湯煎で溶かしたミルクチョコレート１００ｇに製造例５で得られたハゴロモソウのエタノール抽出物１００ｍｇを添加して、よくかき混ぜた後、型に流し込んで冷やして固めた。
Example 5
chocolate:
100 mg of the milk chocolate dissolved in hot water was added with 100 mg of the ethanol extract of Agaricus officinalis obtained in Production Example 5, mixed well, poured into a mold, cooled and solidified.
得られたチョコレートは、食感も良く、味も良好であり、通常のチョコレートに比べて遜色のないものであった。 The obtained chocolate had good texture and good taste, and was comparable to ordinary chocolate.
本発明のグリケーション阻害剤は、高いグリケーション阻害効果を有し、グリケーション或いはグリケーションによって生じる終末糖化物質（ＡＧＥ）等の蓄積によって引き起こされる、各種組織障害の予防及び治療・改善効果を得ることができるものである。また、本発明のグリケーション阻害剤の有効成分は植物由来のため安全性が高いものである。 INDUSTRIAL APPLICABILITY The glycation inhibitor of the present invention has a high glycation inhibitory effect, and provides a preventive, therapeutic, and ameliorating effect for various tissue disorders caused by glycation or accumulation of advanced glycated substances (AGE) generated by glycation. Is what you can do. The active ingredient of the glycation inhibitor of the present invention is of high safety because it is derived from plants.
従って、本発明のグリケーション阻害剤は、医薬品や医薬部外品として使用することができ、また化粧品や飲食品等に配合することができるものである。 Therefore, the glycation inhibitor of the present invention can be used as pharmaceuticals and quasi-drugs, and can be added to cosmetics, foods and drinks, and the like.
Claims (7)
An external preparation comprising the glycation inhibitor according to claim 1 and having a preventive / treating effect on tissue damage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004021332A JP4979181B2 (en) | 2003-01-31 | 2004-01-29 | Glycation inhibitors and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003023230 | 2003-01-31 | ||
| JP2003023230 | 2003-01-31 | ||
| JP2004021332A JP4979181B2 (en) | 2003-01-31 | 2004-01-29 | Glycation inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010134667A Division JP2010248212A (en) | 2003-01-31 | 2010-06-14 | Glycation inhibitor and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004250445A true JP2004250445A (en) | 2004-09-09 |
| JP4979181B2 JP4979181B2 (en) | 2012-07-18 |
Family
ID=33032234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004021332A Expired - Fee Related JP4979181B2 (en) | 2003-01-31 | 2004-01-29 | Glycation inhibitors and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4979181B2 (en) |
Cited By (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006199610A (en) * | 2005-01-19 | 2006-08-03 | Kao Corp | Wrinkle-improving agent |
| JP2006225297A (en) * | 2005-02-16 | 2006-08-31 | Fancl Corp | Agent for treating/preventing obesity, hyperlipemia and arteriosclerotic disease |
| JP2006241141A (en) * | 2005-02-01 | 2006-09-14 | Fancl Corp | Composition for inhibiting angiogenesis |
| JP2006273811A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor |
| JP2007105015A (en) * | 2005-10-17 | 2007-04-26 | House Foods Corp | Method for producing food decreased in acrylamide |
| JP2007119373A (en) * | 2005-10-26 | 2007-05-17 | Arkray Inc | Maillard reaction product-decomposing agent and drink or food using the same |
| JP2007161663A (en) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | Ages-decomposing cosmetic |
| JP2007161661A (en) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | Cosmetic for decomposing advanced glycation endproducts and method for producing the same |
| JP2007210965A (en) * | 2006-02-10 | 2007-08-23 | Univ Of Tokushima | Tyrosinase activity inhibitor, manufacturing method and use thereof |
| JP2007223977A (en) * | 2006-02-24 | 2007-09-06 | Tohoku Univ | Material for inhibiting succharification of aminophospholipid |
| JP2007254345A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor, skin care preparation containing the same and food and beverage |
| JP2007269728A (en) * | 2006-03-31 | 2007-10-18 | Sun Chlorella Corp | Food and drink composition |
| WO2007069204A3 (en) * | 2005-12-14 | 2007-10-25 | Massimelli Daniele Maria | Antiviral, virucid and immunomodulant officinal plant-based composition and related method for the treatment of viral diseases, in particular of hiv infection. |
| JP2007302661A (en) * | 2006-05-08 | 2007-11-22 | Sung Jin Kim | Pharmaceutical composition containing rubi fructus extract for preventing and treating anxiety, depression, and dementia, and promoting one's memory |
| JP2007330191A (en) * | 2006-06-16 | 2007-12-27 | Nihon Yobo Igaku Kenkyusho:Kk | Food suppressing maillard reaction |
| JP2008024601A (en) * | 2006-07-18 | 2008-02-07 | Naris Cosmetics Co Ltd | Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same |
| JP2008088102A (en) * | 2006-09-29 | 2008-04-17 | Kobayashi Pharmaceut Co Ltd | Glycosylation inhibitor |
| WO2008114536A1 (en) * | 2007-03-20 | 2008-09-25 | Arkray, Inc. | Dehydroepiandrosterone production promoter and use thereof |
| US7498049B1 (en) * | 2007-01-03 | 2009-03-03 | Shmuel Gonen | Topical treatment of acne with combined herbal extracts and minerals |
| JP2009057381A (en) * | 2007-08-08 | 2009-03-19 | Nishihara Group:Kk | Deodorant tablet for oral use, deodorant powder for oral use, method for producing deodorant tablet for oral use, and method for producing deodorant powder for oral use |
| WO2009057126A1 (en) * | 2007-10-29 | 2009-05-07 | Avesthagen Limited | A synergistic herbal composition and a process of preparation thereof |
| JP2009161522A (en) * | 2007-12-11 | 2009-07-23 | Hayashibara Biochem Lab Inc | Inhibitor for renal dysfunction |
| WO2009110546A1 (en) * | 2008-03-06 | 2009-09-11 | 独立行政法人産業技術総合研究所 | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same |
| WO2009133586A1 (en) * | 2008-04-28 | 2009-11-05 | 有限会社アンティアンティ | Remedy for alzheimer's disease |
| JP2009256365A (en) * | 2009-07-14 | 2009-11-05 | Lotte Co Ltd | Histamine liberation inhibitor, food and drink containing the same |
| JP2009269834A (en) * | 2008-05-01 | 2009-11-19 | Dhc Co | Bone resorption inhibitor, food and drink for bone resorption inhibition and quasi drug |
| WO2010005004A1 (en) * | 2008-07-07 | 2010-01-14 | 花王株式会社 | Xanthine oxidase inhibitor and uric acid production inhibitor |
| JP2010500974A (en) * | 2006-08-01 | 2010-01-14 | ピエール ファーブル メディカモン | Novel eucalyptus extract, preparation method thereof and therapeutic use thereof |
| JP2010070468A (en) * | 2008-09-16 | 2010-04-02 | Pola Chem Ind Inc | Decomposing agent for advanced glycation end product, and cosmetic containing the decomposing agent for advanced glycation end-product |
| JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
| JP2010513431A (en) * | 2006-12-20 | 2010-04-30 | マース インコーポレーテッド | Oral hygiene composition |
| WO2010056091A2 (en) * | 2008-11-17 | 2010-05-20 | Dongguk University Industry-Academic Cooperation Foundation | Functional sauce for cooking meat including lotus and olive leaf extracts and meat-processed food including the same |
| JP2010115197A (en) * | 2008-11-13 | 2010-05-27 | Kikkoman Singapore R & D Lab Pte Ltd | Enriched liquid seasoning for food |
| JP2010530413A (en) * | 2007-06-20 | 2010-09-09 | バイオケア カンパニ−リミテッド | Use of lignan compounds to improve wrinkles |
| JP2010215585A (en) * | 2009-03-18 | 2010-09-30 | Kobayashi Pharmaceutical Co Ltd | Hepatopathy inhibitor |
| JP2010533142A (en) * | 2007-07-09 | 2010-10-21 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | Inhibition of AGE formation |
| JP2011068583A (en) * | 2009-09-25 | 2011-04-07 | Shiseido Co Ltd | Protein glycation inhibitor |
| JP2011184346A (en) * | 2010-03-08 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | Hyaluronic acid production promoter and cosmetic |
| JP2011195502A (en) * | 2010-03-19 | 2011-10-06 | Shiseido Co Ltd | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent |
| JP2011236241A (en) * | 2011-07-28 | 2011-11-24 | Fancl Corp | Treatment and preventive agent for obesity, hyperlipidemia and arteriosclerotic disease |
| JP2011246353A (en) * | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
| JP2011246354A (en) * | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
| JP2012006876A (en) * | 2010-06-25 | 2012-01-12 | Sansho Seiyaku Co Ltd | Method for producing stable lonicera japonica extract liquid |
| JP2012012385A (en) * | 2010-05-31 | 2012-01-19 | Shiseido Co Ltd | Sympathetic nerve activator, and cosmetic, food and sundries containing the same |
| JP2012131822A (en) * | 2012-03-12 | 2012-07-12 | Lotte Co Ltd | Activator of ciliary movement, and food and drink containing the same |
| CN102648968A (en) * | 2011-02-26 | 2012-08-29 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| CN102657782A (en) * | 2012-05-10 | 2012-09-12 | 日照金豆粮油有限公司 | Method for preparing medicinal tea for preventing upper respiratory tract infection |
| JP2013014627A (en) * | 2012-10-22 | 2013-01-24 | Naris Cosmetics Co Ltd | Heparin-binding epidermal growth factor-like growth factor (hb-egf) production promoter |
| CN103142752A (en) * | 2013-02-08 | 2013-06-12 | 安耀苍 | Urinary calculus treatment medicine and its preparation method |
| WO2013146891A1 (en) * | 2012-03-30 | 2013-10-03 | 株式会社資生堂 | Subcutaneous fat accumulation inhibitor |
| JP2013209339A (en) * | 2012-03-30 | 2013-10-10 | Shiseido Co Ltd | Apj activation agent |
| JP2013253072A (en) * | 2012-02-03 | 2013-12-19 | Chizu Corporation | Protein glycation reaction inhibitor |
| JP2014037447A (en) * | 2013-11-29 | 2014-02-27 | Pola Chem Ind Inc | Production method of skin external agent for pretreatment |
| JP2014037448A (en) * | 2013-11-29 | 2014-02-27 | Pola Chem Ind Inc | Production method of skin external agent against aging |
| JP2014118365A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
| JP2014141484A (en) * | 2012-12-27 | 2014-08-07 | Koji Niina | Absorbing material and soap, face lotion and drinking water using the same |
| CN104013551A (en) * | 2014-06-18 | 2014-09-03 | 黄仕敢 | Anti-wrinkle essence and preparation method thereof |
| JP2015013837A (en) * | 2013-07-05 | 2015-01-22 | ソマール株式会社 | PPARγ ACTIVITY IMPROVER AND ORAL COMPOSITION USING THE SAME |
| ES2536121A1 (en) * | 2013-11-19 | 2015-05-20 | Francisca CORTÉS DÍAZ | Natural lotion for the preparation of oils and creams (Machine-translation by Google Translate, not legally binding) |
| CN104721614A (en) * | 2015-03-03 | 2015-06-24 | 王斌 | Traditional Chinese medicine preparation for treating dearticulation and preparation method of traditional Chinese medicine preparation |
| EP2949362A1 (en) * | 2014-05-26 | 2015-12-02 | ARKRAY, Inc. | Ages-degrading agent and use thereof |
| RU2578453C1 (en) * | 2015-04-23 | 2016-03-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" | Collection of medicinal plants of nootropic action |
| JP2016088933A (en) * | 2014-11-01 | 2016-05-23 | 育宏 南 | Age production inhibitor and application thereof |
| JP2016132633A (en) * | 2015-01-19 | 2016-07-25 | 農業生産法人 有限会社十津川農場 | Alzheimer's disease preventive or therapeutic action of nejime biwa tea |
| JP2017031185A (en) * | 2016-09-21 | 2017-02-09 | 一丸ファルコス株式会社 | Kinesin inhibitor |
| JP2017100991A (en) * | 2015-12-01 | 2017-06-08 | 花王株式会社 | Epidermis cml formation inhibitor |
| JP2017210474A (en) * | 2016-05-23 | 2017-11-30 | アークレイ株式会社 | Maillard reaction product-decomposing agent |
| JP2018002729A (en) * | 2011-05-10 | 2018-01-11 | 丸善製薬株式会社 | Tie2 activator, neovascularization inhibitor, agent for blood vessel maturation, blood vessel normalizer, blood vessel stabilizer, pharmaceutical composition, and foods and beverages |
| JP2018007612A (en) * | 2016-07-13 | 2018-01-18 | 株式会社岡安商店 | Dietary fiber having protein saccharization suppression function and method for producing the same |
| JP2018020990A (en) * | 2016-08-05 | 2018-02-08 | 共栄化学工業株式会社 | External preparation for skin |
| CN113329757A (en) * | 2018-11-14 | 2021-08-31 | 芬策尔贝格有限两合公司 | Use of Leptoradix lemonae extract for enhancing neurocerebrum utilization rate of neurotransmitter such as serotonin, dopamine, norepinephrine, etc |
| US20210290714A1 (en) * | 2018-09-14 | 2021-09-23 | National Guard Health Affairs | Composition and method for treating skin disorders |
| AT17388U1 (en) * | 2020-07-20 | 2022-03-15 | Better For Me Handels Gmbh | Composition containing several plant extracts |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04321615A (en) * | 1991-04-19 | 1992-11-11 | Kose Corp | Skin medicine for external use |
| JPH05246837A (en) * | 1992-03-09 | 1993-09-24 | Mikimoto Pharmaceut Co Ltd | Cosmetic |
| JPH08333267A (en) * | 1995-06-02 | 1996-12-17 | Maruzen Pharmaceut Co Ltd | Antiallergic agent |
| JPH09176019A (en) * | 1995-12-26 | 1997-07-08 | Suntory Ltd | Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith |
| JPH10330221A (en) * | 1997-06-02 | 1998-12-15 | Pola Chem Ind Inc | Enderonic collagen fasciculus remedial agent |
| JPH10330222A (en) * | 1997-06-03 | 1998-12-15 | Pola Chem Ind Inc | Enderonic collagen fasciculus remedial agent |
| JPH1129472A (en) * | 1997-07-07 | 1999-02-02 | Res Inst For Prod Dev | Compound having inhibitory effect against alpha-glucosidase |
| JPH11106336A (en) * | 1997-10-01 | 1999-04-20 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JPH11263720A (en) * | 1998-03-13 | 1999-09-28 | Shiseido Co Ltd | Antiaging agent |
| JPH11292784A (en) * | 1998-04-07 | 1999-10-26 | Noevir Co Ltd | Preparation for external use for skin |
| JP2001122757A (en) * | 1999-10-22 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger, antioxidant and cosmetic |
| JP2001131046A (en) * | 1999-11-04 | 2001-05-15 | Pola Chem Ind Inc | Hydrogen peroxide eliminant and cosmetic material containing the same |
| JP2002020784A (en) * | 2000-07-12 | 2002-01-23 | Maruzen Pharmaceut Co Ltd | Deterioration inhibitor for perfume |
| JP2002205950A (en) * | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor and cosmetic composition |
| JP2002241299A (en) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | Maillard reaction recovering agent |
| JP2003212774A (en) * | 2002-01-22 | 2003-07-30 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JP2003212770A (en) * | 2002-01-22 | 2003-07-30 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JP2003212749A (en) * | 2002-01-16 | 2003-07-30 | Noevir Co Ltd | INHIBITOR OF AGEs FORMATION AND SKIN CARE PREPARATION COMPRISING THE SAME |
| WO2004039388A1 (en) * | 2002-10-30 | 2004-05-13 | Taisho Pharmaceutical Co.,Ltd | α-GLUCOSIDASE INHIBITOR |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
-
2004
- 2004-01-29 JP JP2004021332A patent/JP4979181B2/en not_active Expired - Fee Related
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04321615A (en) * | 1991-04-19 | 1992-11-11 | Kose Corp | Skin medicine for external use |
| JPH05246837A (en) * | 1992-03-09 | 1993-09-24 | Mikimoto Pharmaceut Co Ltd | Cosmetic |
| JPH08333267A (en) * | 1995-06-02 | 1996-12-17 | Maruzen Pharmaceut Co Ltd | Antiallergic agent |
| JPH09176019A (en) * | 1995-12-26 | 1997-07-08 | Suntory Ltd | Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith |
| JPH10330221A (en) * | 1997-06-02 | 1998-12-15 | Pola Chem Ind Inc | Enderonic collagen fasciculus remedial agent |
| JPH10330222A (en) * | 1997-06-03 | 1998-12-15 | Pola Chem Ind Inc | Enderonic collagen fasciculus remedial agent |
| JPH1129472A (en) * | 1997-07-07 | 1999-02-02 | Res Inst For Prod Dev | Compound having inhibitory effect against alpha-glucosidase |
| JPH11106336A (en) * | 1997-10-01 | 1999-04-20 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JPH11263720A (en) * | 1998-03-13 | 1999-09-28 | Shiseido Co Ltd | Antiaging agent |
| JPH11292784A (en) * | 1998-04-07 | 1999-10-26 | Noevir Co Ltd | Preparation for external use for skin |
| JP2001122757A (en) * | 1999-10-22 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger, antioxidant and cosmetic |
| JP2001131046A (en) * | 1999-11-04 | 2001-05-15 | Pola Chem Ind Inc | Hydrogen peroxide eliminant and cosmetic material containing the same |
| JP2002020784A (en) * | 2000-07-12 | 2002-01-23 | Maruzen Pharmaceut Co Ltd | Deterioration inhibitor for perfume |
| JP2002205950A (en) * | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor and cosmetic composition |
| JP2002241299A (en) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | Maillard reaction recovering agent |
| JP2003212749A (en) * | 2002-01-16 | 2003-07-30 | Noevir Co Ltd | INHIBITOR OF AGEs FORMATION AND SKIN CARE PREPARATION COMPRISING THE SAME |
| JP2003212774A (en) * | 2002-01-22 | 2003-07-30 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JP2003212770A (en) * | 2002-01-22 | 2003-07-30 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| WO2004039388A1 (en) * | 2002-10-30 | 2004-05-13 | Taisho Pharmaceutical Co.,Ltd | α-GLUCOSIDASE INHIBITOR |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| 富山県薬事研究所年報, JPN6010018069, 1998, JP, pages 49 - 52, ISSN: 0001586148 * |
Cited By (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006199610A (en) * | 2005-01-19 | 2006-08-03 | Kao Corp | Wrinkle-improving agent |
| JP2006241141A (en) * | 2005-02-01 | 2006-09-14 | Fancl Corp | Composition for inhibiting angiogenesis |
| JP2006225297A (en) * | 2005-02-16 | 2006-08-31 | Fancl Corp | Agent for treating/preventing obesity, hyperlipemia and arteriosclerotic disease |
| JP2006273811A (en) * | 2005-03-30 | 2006-10-12 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor |
| JP2007105015A (en) * | 2005-10-17 | 2007-04-26 | House Foods Corp | Method for producing food decreased in acrylamide |
| JP2007119373A (en) * | 2005-10-26 | 2007-05-17 | Arkray Inc | Maillard reaction product-decomposing agent and drink or food using the same |
| WO2007069204A3 (en) * | 2005-12-14 | 2007-10-25 | Massimelli Daniele Maria | Antiviral, virucid and immunomodulant officinal plant-based composition and related method for the treatment of viral diseases, in particular of hiv infection. |
| JP2007161661A (en) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | Cosmetic for decomposing advanced glycation endproducts and method for producing the same |
| JP2007161663A (en) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | Ages-decomposing cosmetic |
| JP2007210965A (en) * | 2006-02-10 | 2007-08-23 | Univ Of Tokushima | Tyrosinase activity inhibitor, manufacturing method and use thereof |
| JP2007223977A (en) * | 2006-02-24 | 2007-09-06 | Tohoku Univ | Material for inhibiting succharification of aminophospholipid |
| JP2007254345A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Maillard reaction inhibitor, skin care preparation containing the same and food and beverage |
| JP2007269728A (en) * | 2006-03-31 | 2007-10-18 | Sun Chlorella Corp | Food and drink composition |
| JP2007302661A (en) * | 2006-05-08 | 2007-11-22 | Sung Jin Kim | Pharmaceutical composition containing rubi fructus extract for preventing and treating anxiety, depression, and dementia, and promoting one's memory |
| JP2007330191A (en) * | 2006-06-16 | 2007-12-27 | Nihon Yobo Igaku Kenkyusho:Kk | Food suppressing maillard reaction |
| JP2008024601A (en) * | 2006-07-18 | 2008-02-07 | Naris Cosmetics Co Ltd | Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same |
| JP2010500974A (en) * | 2006-08-01 | 2010-01-14 | ピエール ファーブル メディカモン | Novel eucalyptus extract, preparation method thereof and therapeutic use thereof |
| JP2008088102A (en) * | 2006-09-29 | 2008-04-17 | Kobayashi Pharmaceut Co Ltd | Glycosylation inhibitor |
| JP2010513431A (en) * | 2006-12-20 | 2010-04-30 | マース インコーポレーテッド | Oral hygiene composition |
| US7498049B1 (en) * | 2007-01-03 | 2009-03-03 | Shmuel Gonen | Topical treatment of acne with combined herbal extracts and minerals |
| WO2008114536A1 (en) * | 2007-03-20 | 2008-09-25 | Arkray, Inc. | Dehydroepiandrosterone production promoter and use thereof |
| JP2008231031A (en) * | 2007-03-20 | 2008-10-02 | Arkray Inc | Dehydroepiandrosterone production promoter and use thereof |
| KR101404398B1 (en) * | 2007-06-20 | 2014-06-09 | (주)뉴트리 | Anti-wrinkle cosmetic composition |
| JP2017222653A (en) * | 2007-06-20 | 2017-12-21 | バイオケア カンパニ−リミテッド | Use of lignan compound for anti-wrinkle treatment |
| JP2016155842A (en) * | 2007-06-20 | 2016-09-01 | バイオケア カンパニ−リミテッド | Use of lignan compound for anti-wrinkle treatment |
| JP2014221804A (en) * | 2007-06-20 | 2014-11-27 | バイオケア カンパニ−リミテッド | Use of lignan compound for anti-wrinkle treatment |
| JP2010530413A (en) * | 2007-06-20 | 2010-09-09 | バイオケア カンパニ−リミテッド | Use of lignan compounds to improve wrinkles |
| EP2170255A4 (en) * | 2007-06-20 | 2013-12-04 | Biocare Co Ltd | Use of lignan compound for anti-wrinkle treatment |
| JP2014088381A (en) * | 2007-07-09 | 2014-05-15 | Basf Beauty Care Solutions France Sas | Inhibition of formation of age |
| JP2010533142A (en) * | 2007-07-09 | 2010-10-21 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | Inhibition of AGE formation |
| JP2009057381A (en) * | 2007-08-08 | 2009-03-19 | Nishihara Group:Kk | Deodorant tablet for oral use, deodorant powder for oral use, method for producing deodorant tablet for oral use, and method for producing deodorant powder for oral use |
| WO2009057126A1 (en) * | 2007-10-29 | 2009-05-07 | Avesthagen Limited | A synergistic herbal composition and a process of preparation thereof |
| JP2009161522A (en) * | 2007-12-11 | 2009-07-23 | Hayashibara Biochem Lab Inc | Inhibitor for renal dysfunction |
| JP5704484B2 (en) * | 2008-03-06 | 2015-04-22 | 独立行政法人産業技術総合研究所 | Composition comprising Ashwagandha leaf water extract as active ingredient and method for producing the same |
| WO2009110546A1 (en) * | 2008-03-06 | 2009-09-11 | 独立行政法人産業技術総合研究所 | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same |
| WO2009133586A1 (en) * | 2008-04-28 | 2009-11-05 | 有限会社アンティアンティ | Remedy for alzheimer's disease |
| JP2009269834A (en) * | 2008-05-01 | 2009-11-19 | Dhc Co | Bone resorption inhibitor, food and drink for bone resorption inhibition and quasi drug |
| WO2010005004A1 (en) * | 2008-07-07 | 2010-01-14 | 花王株式会社 | Xanthine oxidase inhibitor and uric acid production inhibitor |
| US9827279B2 (en) | 2008-07-07 | 2017-11-28 | Kao Corporation | Xanthine oxidase inhibitor and uric acid production inhibitor |
| JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
| JP2015232025A (en) * | 2008-08-29 | 2015-12-24 | 日本新薬株式会社 | Maillard reaction inhibitor |
| JP2010070468A (en) * | 2008-09-16 | 2010-04-02 | Pola Chem Ind Inc | Decomposing agent for advanced glycation end product, and cosmetic containing the decomposing agent for advanced glycation end-product |
| JP2010115197A (en) * | 2008-11-13 | 2010-05-27 | Kikkoman Singapore R & D Lab Pte Ltd | Enriched liquid seasoning for food |
| WO2010056091A3 (en) * | 2008-11-17 | 2010-08-26 | Dongguk University Industry-Academic Cooperation Foundation | Functional sauce for cooking meat including lotus and olive leaf extracts and meat-processed food including the same |
| WO2010056091A2 (en) * | 2008-11-17 | 2010-05-20 | Dongguk University Industry-Academic Cooperation Foundation | Functional sauce for cooking meat including lotus and olive leaf extracts and meat-processed food including the same |
| JP2010215585A (en) * | 2009-03-18 | 2010-09-30 | Kobayashi Pharmaceutical Co Ltd | Hepatopathy inhibitor |
| JP2009256365A (en) * | 2009-07-14 | 2009-11-05 | Lotte Co Ltd | Histamine liberation inhibitor, food and drink containing the same |
| JP2011068583A (en) * | 2009-09-25 | 2011-04-07 | Shiseido Co Ltd | Protein glycation inhibitor |
| JP2011184346A (en) * | 2010-03-08 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | Hyaluronic acid production promoter and cosmetic |
| JP2011195502A (en) * | 2010-03-19 | 2011-10-06 | Shiseido Co Ltd | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent |
| JP2011246354A (en) * | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
| JP2011246353A (en) * | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
| JP2012012385A (en) * | 2010-05-31 | 2012-01-19 | Shiseido Co Ltd | Sympathetic nerve activator, and cosmetic, food and sundries containing the same |
| JP2012006876A (en) * | 2010-06-25 | 2012-01-12 | Sansho Seiyaku Co Ltd | Method for producing stable lonicera japonica extract liquid |
| CN102648968A (en) * | 2011-02-26 | 2012-08-29 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| CN102648968B (en) * | 2011-02-26 | 2013-12-18 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| JP2018002729A (en) * | 2011-05-10 | 2018-01-11 | 丸善製薬株式会社 | Tie2 activator, neovascularization inhibitor, agent for blood vessel maturation, blood vessel normalizer, blood vessel stabilizer, pharmaceutical composition, and foods and beverages |
| JP2011236241A (en) * | 2011-07-28 | 2011-11-24 | Fancl Corp | Treatment and preventive agent for obesity, hyperlipidemia and arteriosclerotic disease |
| JP2013253072A (en) * | 2012-02-03 | 2013-12-19 | Chizu Corporation | Protein glycation reaction inhibitor |
| JP2012131822A (en) * | 2012-03-12 | 2012-07-12 | Lotte Co Ltd | Activator of ciliary movement, and food and drink containing the same |
| JP2013227289A (en) * | 2012-03-30 | 2013-11-07 | Shiseido Co Ltd | Subcutaneous fat accumulation inhibitor |
| WO2013146891A1 (en) * | 2012-03-30 | 2013-10-03 | 株式会社資生堂 | Subcutaneous fat accumulation inhibitor |
| JP2013209339A (en) * | 2012-03-30 | 2013-10-10 | Shiseido Co Ltd | Apj activation agent |
| JP2013227359A (en) * | 2012-03-30 | 2013-11-07 | Shiseido Co Ltd | Subcutaneous fat accumulation inhibitor |
| CN102657782A (en) * | 2012-05-10 | 2012-09-12 | 日照金豆粮油有限公司 | Method for preparing medicinal tea for preventing upper respiratory tract infection |
| JP2013014627A (en) * | 2012-10-22 | 2013-01-24 | Naris Cosmetics Co Ltd | Heparin-binding epidermal growth factor-like growth factor (hb-egf) production promoter |
| JP2014118365A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
| JP2014141484A (en) * | 2012-12-27 | 2014-08-07 | Koji Niina | Absorbing material and soap, face lotion and drinking water using the same |
| CN103142752A (en) * | 2013-02-08 | 2013-06-12 | 安耀苍 | Urinary calculus treatment medicine and its preparation method |
| JP2015013837A (en) * | 2013-07-05 | 2015-01-22 | ソマール株式会社 | PPARγ ACTIVITY IMPROVER AND ORAL COMPOSITION USING THE SAME |
| ES2536121A1 (en) * | 2013-11-19 | 2015-05-20 | Francisca CORTÉS DÍAZ | Natural lotion for the preparation of oils and creams (Machine-translation by Google Translate, not legally binding) |
| JP2014037448A (en) * | 2013-11-29 | 2014-02-27 | Pola Chem Ind Inc | Production method of skin external agent against aging |
| JP2014037447A (en) * | 2013-11-29 | 2014-02-27 | Pola Chem Ind Inc | Production method of skin external agent for pretreatment |
| EP2949362A1 (en) * | 2014-05-26 | 2015-12-02 | ARKRAY, Inc. | Ages-degrading agent and use thereof |
| CN105125649A (en) * | 2014-05-26 | 2015-12-09 | 爱科来株式会社 | Ages-degrading agent and use thereof |
| CN104013551A (en) * | 2014-06-18 | 2014-09-03 | 黄仕敢 | Anti-wrinkle essence and preparation method thereof |
| JP2016088933A (en) * | 2014-11-01 | 2016-05-23 | 育宏 南 | Age production inhibitor and application thereof |
| JP2016132633A (en) * | 2015-01-19 | 2016-07-25 | 農業生産法人 有限会社十津川農場 | Alzheimer's disease preventive or therapeutic action of nejime biwa tea |
| CN104721614A (en) * | 2015-03-03 | 2015-06-24 | 王斌 | Traditional Chinese medicine preparation for treating dearticulation and preparation method of traditional Chinese medicine preparation |
| RU2578453C1 (en) * | 2015-04-23 | 2016-03-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" | Collection of medicinal plants of nootropic action |
| JP2017100991A (en) * | 2015-12-01 | 2017-06-08 | 花王株式会社 | Epidermis cml formation inhibitor |
| JP2017210474A (en) * | 2016-05-23 | 2017-11-30 | アークレイ株式会社 | Maillard reaction product-decomposing agent |
| JP2018007612A (en) * | 2016-07-13 | 2018-01-18 | 株式会社岡安商店 | Dietary fiber having protein saccharization suppression function and method for producing the same |
| JP2018020990A (en) * | 2016-08-05 | 2018-02-08 | 共栄化学工業株式会社 | External preparation for skin |
| JP2017031185A (en) * | 2016-09-21 | 2017-02-09 | 一丸ファルコス株式会社 | Kinesin inhibitor |
| US20210290714A1 (en) * | 2018-09-14 | 2021-09-23 | National Guard Health Affairs | Composition and method for treating skin disorders |
| US11903987B2 (en) * | 2018-09-14 | 2024-02-20 | National Guard Health Affairs | Artificial compositions comprising corosolic acid, oleanolic acid; and ursolic acid in a form of an emulsion, salve, ointment, suspension, or gel |
| CN113329757A (en) * | 2018-11-14 | 2021-08-31 | 芬策尔贝格有限两合公司 | Use of Leptoradix lemonae extract for enhancing neurocerebrum utilization rate of neurotransmitter such as serotonin, dopamine, norepinephrine, etc |
| AT17388U1 (en) * | 2020-07-20 | 2022-03-15 | Better For Me Handels Gmbh | Composition containing several plant extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4979181B2 (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4979181B2 (en) | Glycation inhibitors and uses thereof | |
| JP2010248212A (en) | Glycation inhibitor and application thereof | |
| JP4658348B2 (en) | Collagen production promoter, collagenase inhibitor, fibroblast proliferation agent, elastase inhibitor, estrogen-like agent, and skin cosmetics | |
| JP2002179586A (en) | Lipase inhibitor | |
| JP5024978B2 (en) | Antioxidant | |
| JP4002654B2 (en) | Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation | |
| JP2011195531A (en) | Protein glycation inhibitor | |
| JP2010159283A (en) | Proanthocyanidin-containing composition | |
| JP2011055837A (en) | Food and drink for beautification | |
| JP2004159563A (en) | Propolis composition | |
| JP2009161497A (en) | Perilla extract, sugar absorption inhibitor containing the same, and pharmaceutical or quasi-drug, and food or drink, each using the same | |
| JP2015017067A (en) | Food products, cosmetics, pharmaceuticals, and animal feed for promoting hair growth or preventing and improving hair loss | |
| JP5156330B2 (en) | Adipose tissue weight reducing agent | |
| JP2003137801A (en) | Collagen production promoter, collagenase inhibitor, fibroblast cell-propagating agent, skin cosmetic material and food or beverage for cosmetic use | |
| JP2019147824A (en) | Kaempferia parviflora-containing compositions | |
| WO2022169066A1 (en) | Functional collagen composition using aurea helianthus-derived collagen amino acid | |
| JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
| KR100478021B1 (en) | Water Soluble Improved Propolis Extract | |
| KR101757841B1 (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
| JP2005060338A (en) | Proanthocyanidin-including composition | |
| JP2002047193A (en) | Composition for prophylaxis or treatment of allergic dermatitis | |
| KR101332531B1 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus acacia | |
| JP4768105B2 (en) | Oral composition | |
| JP2003176230A (en) | Collagen production promoter, elastase inhibitor, collagenase inhibitor and skin cosmetic and beautifying foods or beverage | |
| JP2018009038A (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100614 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100614 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111109 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120417 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150427 Year of fee payment: 3 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 4979181 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| LAPS | Cancellation because of no payment of annual fees |